Introduction {#sec1}
============

Recent advances in biotechnology have revolutionized our ability to understand the genetic basis of human health. The advent of next-generation sequencing technologies and high throughput DNA microarrays have provided crucial tools to define the landscape of human genetic variation through large, international collaborative efforts \[[@B1],[@B2]\]. Today, millions of human reference single nucleotide polymorphisms (SNPs) and structural variants from individuals worldwide are cataloged and publicly available for further investigation \[[@B3]\]. The ability to quickly and thoroughly genotype individuals has enabled researchers to identify numerous genetic loci involved in common and complex diseases through genome-wide association studies \[[@B4],[@B5]\]. Identifying genetic signatures associated with a wide variety of diseases in patients has been helpful in providing appropriate treatments and lifestyle changes to mitigate disease symptoms and improve the quality of life. With the rapid emergence of new genome editing tools, long-lasting or permanent mitigation of genetic diseases through selective modification of the human genome is now possible resulting in immense potential to improve human health.

In this review, we discuss the current state of gene editing technologies and their use as treatments for human disease. We place special emphasis on CRISPR ([c]{.ul}lustered [r]{.ul}egularly [i]{.ul}nterspaced [s]{.ul}hort [p]{.ul}alindromic [r]{.ul}epeat DNA sequences)-based technologies, as they are quickly transforming the state of life science research around the world and progressing into clinical trials. The initial wave of modern-day genome editors (zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)) have been evaluated in clinical trials to some extent, but the use of these technologies has been limited due to the need for difficult and laborious engineering of a new version of the editing protein for each new target in the genome \[[@B6]\]. Most recently, CRISPR, a naturally occurring prokaryotic immune system that evolved across diverse bacteria and archaea to protect themselves from invading viruses \[[@B9],[@B10]\] has been re-purposed into powerful gene editing tools that function efficiently in diverse organisms including humans \[[@B11]\]. In brief, CRISPR-editing involves the use of CRISPR-associated (Cas) enzymes that target and cleave specific nucleic acid sequences. There are numerous identified CRISPR systems, each of which have distinct nucleic acid binding requirements and enzymatic activities, however the majority of CRISPR-based applications to date utilize Cas9 from *Streptococcus pygogenes* (spCas9) \[[@B12]\]. To target specific DNA sequences, Cas9 utilizes a CRISPR RNA (crRNA) with a 20-nucleotide complimentary sequence to the target sequence, and a trans-activating crRNA (tracrRNA) scaffold that is recognized by the Cas9 protein \[[@B13]\]. Importantly, the crRNA and tracrRNA can be fused to form a single guide RNA (sgRNA) chimera that retains the ability to target and cleave specific nucleic acid target sequences \[[@B16]\]. In contrast to early ZFN and TALEN-based editors, CRISPR-based systems require only alteration of the 20-nucleotide target sequence of the sgRNA in order to specifically target a new site in the genome, making the transition between gene targets far more efficient. Because of this, CRISPR-based systems are quickly transforming the state of life science research around the world and progressing into clinical trials. Comprehensive reviews of the history, function, and diversity of ZFN, TALEN, and CRISPR editors have been the subject of many prior reviews and the reader is referred there for introductory material about the function of these powerful editing technologies \[[@B6],[@B12],[@B17]\].

In this review, we will first discuss the state of gene editing technologies and their use as treatments for human disease with a specific focus on CRISPR-based therapies that are currently being tested in ongoing clinical trials. Second, we will present the known limitations for *in vivo* use of gene editors which include off-target effects, delivery issues, and immunogenicity of gene editing molecules. Given the rapid progression of gene editing tools, there are a number of solutions in the research and pre-clinical stages of development that have future potential to address these limitations for clinical use in humans. To conclude this review, we will discuss newly developed technologies that hold promise to address the limitations of current gene editors for clinical use that include the development of new delivery vehicles to direct gene editors to specific tissues, hyperaccurate CRISPR systems that decrease off-target effects, and gene editing tools that modulate the reversible control of gene expression and epigenetics.

Clinical trials with gene editors {#sec2}
=================================

The U.S. clinical trials database (clinicaltrials.gov) contains all studies which meet the definition of an 'applicable clinical trial' initiated on or after 27 September 2007 or continuing beyond 26 December 2007. In addition to trials required to register, voluntary registration is also accepted; studies conducted outside U.S.A., and those which may meet one of the conditions in the future, often register voluntarily. We searched the U.S. clinical trials database (01/01/2020) for any trial containing at least one of the following terms: CRISPR, Cas9, Cas12, Cas13, ZFN, zinc finger, gene edit, gene modification, and genome edit. Trials that did not use the genome editor as part of the therapeutic intervention were excluded from the analysis; these included trials to create cell lines from patients using Cas9; use of patient cells to develop therapeutic strategies, but where the cells were not used as a therapeutic themselves; CRISPR use for genome sequencing; and surveys of opinions regarding human gene editing. This search identified 41 trials utilizing genome editing agents including ZFNs, TALENs, and CRISPR/Cas9 for therapeutic interventions, no studies utilizing Cas12 or Cas13 have been registered ([Table 1](#T1){ref-type="table"}). Genome editing agents have clinically been utilized in two ways ([Figure 1](#F1){ref-type="fig"}): cells can be removed from the patient or donor and modified outside the body (*ex vivo*) followed by reinfusion into the patient or the genome editor itself can be injected into the patient (*in vivo).* Of the registered trials, 37 were *ex vivo* delivery and only 8 were *in vivo* delivery.

![Genome editors can be used therapeutically in several ways, and both *ex vivo* and *in vivo* delivery for somatic genome editing have advanced to clinical trial\
*Ex vivo*: cells can be extracted from the patient or donor modified in the laboratory and then infused into the patient. *In vivo*: delivery vehicles, including viral vectors and nanoparticles can be loaded with the genome editor and then injected into the patient either systemically, which results in liver editing primarily, or into the location of interest, for example, the eye.](bsr-40-bsr20200127-g1){#F1}

###### Interventional trials with genome editors

  Delivery vector                                  Nuclease   Phase       Target gene and effect                                                    Disease                                         *Ex vivo/in vivo*   Intervention                                                                                                                                      Sponsor organization                                                              Country                         NCT number    Date posted
  ------------------------------------------------ ---------- ----------- ------------------------------------------------------------------------- ----------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------- ------------- -------------
  Adenoviral vectors                               ZFN        I           CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           University of Pennsylvania                                                        U.S.A.                          NCT00842634   2/12/2009
                                                   ZFN        I           CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           Sangamo Biosciences                                                               U.S.A.                          NCT01044654   1/8/2010
                                                   ZFN        I/II        CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           Sangamo Biosciences                                                               U.S.A.                          NCT01252641   12/3/2010
                                                   ZFN        I/II        CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           Sangamo Biosciences                                                               U.S.A.                          NCT01543152   3/2/2012
                                                   ZFN        I/II        CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           Case Western Reserve University                                                   U.S.A.                          NCT03666871   9/12/2018
  AAV vectors                                      ZFN        I           Factor IX addition al albumin locus                                       Hemophilia B                                    *In vivo*           ZFN-mediated addition of Factor IX gene to the albumin locus of hepatocytes                                                                       Sangamo Biosciences                                                               U.S.A.                          NCT02695160   3/1/2016
                                                   ZFN        I           α-L-iduronidase (IDUA) addition at albumin locus                          MPS type I                                      *In vivo*           ZFN-mediated addition of *IDUA* gene to the albumin locus of hepatocytes                                                                          Sangamo Biosciences                                                               U.S.A.                          NCT02702115   3/8/2016
                                                   ZFN        I           Iduronate 2-sulfatase (IDS) addition at albumin locus                     MPS type II                                     *In vivo*           ZFN-mediated addition of *IDS* gene to the albumin locus of hepatocytes                                                                           Sangamo Biosciences                                                               U.S.A.                          NCT03041324   2/2/2017
                                                   Cas9       I           Removal of alternative splice site in CEP290                              Leber congenital amaurosis 10                   *In vivo*           ZFN-mediated removal of intronic alternative splice site in retinal cells                                                                         Allergan and Editas Medicine, Inc.                                                U.S.A.                          NCT03872479   3/13/2019
  Electroporation (mRNA)                           ZFN        I/II        CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           Sangamo Biosciences                                                               U.S.A.                          NCT02225665   8/26/2014
                                                   ZFN        I           CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells                                                                                                                           University of Pennsylvania                                                        U.S.A.                          NCT02388594   3/17/2015
                                                   ZFN        I           CCR5 knockout                                                             HIV                                             *ex vivo*           Modified CD34^+^ hematopoietic stem cells                                                                                                         City of Hope Medical Center                                                       U.S.A.                          NCT02500849   7/17/2015
                                                   ZFN        I/II        Disrupt the erythroid enhancer in B-cell lymphoma/leukemia 11A (BCL11A)   β-thalassemia                                   *Ex vivo*           Modified hematopoietic stem cells                                                                                                                 Sangamo Biosciences                                                               U.S.A.                          NCT03432364   2/14/2018
                                                   ZFN        I           CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified T cells with ZFN-mediated CCR5 deletion as well as the addition of CD4 CAR receptor and modified CXCR4 expression                        University of Pennsylvania                                                        U.S.A.                          NCT03617198   8/6/2018
                                                   ZFN        I/II        Disrupt B-cell lymphoma/leukemia 11A (BCL11A)                             sickle cell anemia                              *Ex vivo*           Modified hematopoietic stem cells                                                                                                                 Bioverativ                                                                        U.S.A.                          NCT03653247   8/31/2018
                                                   TALEN      I           TCRα, TCRβ, CD52 knockout                                                 Advanced lymphoid malignancy                    *Ex vivo*           CD19-CAR modified T cells with CAR delivered by lentivirus and TALEN knockout CD52 and TCR to create universal T cells                            Institut de Recherches Internationales Servier                                    U.K., U.S.A., France            NCT02746952   4/21/2016
                                                   TALEN      I           TCRα, TCRβ, CD52 knockout                                                 Refractory B-ALL                                *Ex vivo*           CD19-CAR modified T cells with CAR delivered by lentivirus and TALEN knockout CD52 and TCR to create universal T-cells                            Institut de Recherches Internationales Servier                                    U.K., Belgium, France, U.S.A.   NCT02808442   6/21/2016
                                                   TALEN      I           Programmed cell death 1 (PD-1) and CD52 knockout                          Acute myeloid leukemia                          *Ex vivo*           CD123-CAR modified T cells with CAR delivered by lentivirus and TALEN-mediated knockouts                                                          Cellectis S.A.                                                                    U.S.A.                          NCT03190278   6/16/2017
                                                   TALEN      I           Programmed cell death 1 (PD-1) and CD52 knockout                          Blastic plasmacytoid dendritic cell neoplasm    *Ex vivo*           CD123-CAR modified T cells with CAR delivered by lentivirus and TALEN-mediated knockouts                                                          Cellectis S.A.                                                                    U.S.A.                          NCT03203369   6/29/2017
                                                   TALEN      I           Programmed cell death 1 (PD-1) and CD52 knockout                          Acute myeloid leukemia                          *Ex vivo*           CD123-CAR modified T cells with CAR delivered by lentivirus and TALEN-mediated knockouts                                                          Cellectis S.A.                                                                    U.S.A.                          NCT04106076   9/23/2019
                                                   TALEN      I           Programmed cell death 1 (PD-1) and CD52 knockout                          Multiple myeloma                                *Ex vivo*           CS-1-CAR modified T cells with CAR delivered by lentivirus and TALEN-mediated knockouts                                                           Cellectis S.A.                                                                    U.S.A.                          NCT04142619   10/29/2019
                                                   TALEN      I           Programmed cell death 1 (PD-1) and CD52 knockout                          CD22^+^ B cell acute lymphoblastic leukemia     *Ex vivo*           CD22-CAR modified T cells with CAR delivered by lentivirus and TALEN-mediated knockouts                                                           Cellectis S.A.                                                                    U.S.A.                          NCT04150497   11/4/2019
                                                   Cas9       I/II        βTCRα, TCRβ, β-2 microglobin (B2M) knockout                               B-cell leukemia                                 *Ex vivo*           CD19-CAR modified T cells with CAR delivered by lentivirus and Cas9 knockout B2M and TCR to create universal T cells                              Chinese PLA General Hospital                                                      China                           NCT03166878   5/25/2017
                                                   Cas9       I           TCRα, TCRβ, PD-1 knockout                                                 Various malignancies                            *Ex vivo*           Modified T cells with Cas9-mediated deletions and lentiviral transduction of NY-ESO-1 targeted TCR                                                University of Pennsylvania                                                        U.S.A.                          NCT03399448   1/16/2018
                                                   Cas9       I/II        Disruption of the erythroid enhancer to *BCL11A* gene                     β-thalassemia                                   *Ex vivo*           *Ex vivo* modified hematopoietic stem cells                                                                                                       CRISPR Therapeutics                                                               U.K., Germany                   NCT03655678   8/31/2018
                                                   Cas9       I/II        Disruption of the erythroid enhancer to *BCL11A* gene                     Sickle cell anemia                              *Ex vivo*           *Ex vivo* modified hematopoietic stem cells                                                                                                       Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics                       U.S.A.                          NCT03745287   11/19/2018
                                                   Cas9       I/II        Creation of a CD19-directed T cell                                        Refractory B-cell malignancies                  *Ex vivo*           CD19-directed T-cell immunotherapy                                                                                                                CRISPR Therapeutics                                                               U.S.A., Australia               NCT04035434   7/29/2019
                                                   Cas9       I           disruption of HPK1                                                        refractory B cell malignancies                  *Ex vivo*           CD19-CAR modified T cells with CAR delivered by lentivirus and Cas9 knockout of HPK1                                                              Xijing Hospital                                                                   China                           NCT04037566   7/30/2019
  plasmid delivery                                 ZFN        I           E7 oncogene of HPV16 and HPV18 deletion                                   HPV-related malignancy                          *In vivo*           Vaginal suppository with polymer to facilitate delivery                                                                                           Huazhong University of Science and Technology                                     China                           NCT02800369   6/15/2016
                                                   TALEN      I           E6 and E7 oncogene of HPV16 and HPV18 deletion                            HPV-related malignancy                          *in vivo*           plasmid in a gel containing a polymer to facilitate delivery                                                                                      First Affiliated Hospital, Sun Yat-Sen University                                 China                           NCT03057912   2/20/2017
                                                   TALEN      I           E6 and E7 oncogene of HPV16 and HPV18 deletion                            HPV-related malignancy                          *In vivo*           Plasmid in vaginal suppository with polymer to facilitate delivery                                                                                Huazhong University of Science and Technology                                     China                           NCT03226470   7/21/2017
                                                   Cas9       I           E6 and E7 oncogene of HPV16 and HPV18 deletion                            HPV-related malignancy                          *In vivo*           Plasmid in a gel containing a polymer to facilitate delivery                                                                                      First Affiliated Hospital, Sun Yat-Sen University                                 China                           NCT03057912   2/20/2017
  Undefined, likely electroporation                Cas9       I           Programmed cell death protein 1 (PD-1) knockout                           Metastatic non-small cell lung cancer           *Ex vivo*           Modified T cells                                                                                                                                  Peking University                                                                 China                           NCT02793856   6/8/2016
                                                   Cas9       I           Programmed cell death protein 1 (PD-1) knockout                           Stage IV bladder cancer                         *Ex vivo*           Modified T cells                                                                                                                                  Peking University                                                                 China                           NCT02863913   8/11/2016
                                                   Cas9       I           Programmed cell death protein 1 (PD-1) knockout                           Metastatic renal cell carcinoma                 *Ex vivo*           Modified T cells                                                                                                                                  Peking University                                                                 China                           NCT02867332   8/15/2016
                                                   Cas9       I           Programmed cell death protein 1 (PD-1) knockout                           Hormone refractory prostate cancer              *Ex vivo*           Modified T cells                                                                                                                                  Peking University                                                                 China                           NCT02867345   8/15/2016
                                                   Cas9       I/II        Programmed cell death protein 1 (PD-1) knockout                           EBV-positive, advanced stage malignancies       *Ex vivo*           Modified T cells selected for those targeting EBV positive cells                                                                                  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School   China                           NCT03044743   2/7/2017
                                                   Cas9       II          Programmed cell death protein 1 (PD-1) knockout                           esophageal cancer                               *Ex vivo*           Modified T cells                                                                                                                                  Hangzhou Cancer Center                                                            China                           NCT03081715   3/16/2017
                                                   Cas9       n/a         CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD34^+^ hematopoietic stem cells                                                                                                         Affiliated Hospital to Academy of Military Medical Sciences                       China                           NCT03164135   5/23/2017
                                                   Cas9       I/II        Cas9-mediated creation of CD19 and CD20 or CD19 and CD22 CAR-T cells      Leukemia                                        *Ex vivo*           CAR T cells to CD19 and CD20 or CD19 and CD22                                                                                                     Chinese PLA General Hospital                                                      China                           NCT03398967   1/16/2018
                                                   Cas9       I/II        Cytokine-induced SH2 protein (CISH) knockout                              Metastatic gastrointestinal epithelial cancer   *Ex vivo*           Modified tumor-infiltrating lymphocytes                                                                                                           National Cancer Institute                                                         U.S.A.                          NCT03538613   5/28/2018
                                                   Cas9       I           Programmed cell death protein 1 (PD-1) and TCR knockout                   Mesothelin positive solid tumors                *Ex vivo*           CAR T cells to mesothelin with added PD-1 and TCR knockout                                                                                        Chinese PLA General Hospital                                                      China                           NCT03545815   6/4/2018
                                                   Cas9       I           CD7 knockout in CD7 CAR T cells                                           T-cell malignancies                             *Ex vivo*           CAR T cells to CD7 and knockout of native CD7 to prevent self targeting                                                                           Baylor College of Medicine                                                        U.S.A.                          NCT03690011   10/1/2018
                                                   Cas9       I           Correction of the hemoglobulin subunit β globulin gene                    β-thalassemia                                   *Ex vivo*           *Ex vivo* modified hematopoietic stem cells                                                                                                       Allife Medical Science and Technology Co., Ltd.                                   Not specified                   NCT03728322   11/2/2018
                                                   Cas9       I           Programmed cell death protein 1 (PD-1) knockout                           Mesothelin positive solid tumors                *Ex vivo*           CAR T cells to mesothelin with PD-1 knockout                                                                                                      Chinese PLA General Hospital                                                      China                           NCT03747965   11/20/2018
                                                   Cas9       I/II        Cytokine-induced SH2 protein (CISH) knockout                              Metastatic gastrointestinal epithelial cancer   *Ex vivo*           Modified tumor infiltrating lymphocytes                                                                                                           Masonic Cancer Center, University of Minnesota                                    U.S.A.                          NCT04089891   9/13/2019
  Long-term clinical follow-up post-intervention   ZFN        Follow-up   CCR5 knockout                                                             HIV                                             *Ex vivo*           Modified CD4^+^ T cells, 12-year follow-up study                                                                                                  Sangamo Biosciences                                                               U.S.A.                          NCT04201782   12/17/2019
                                                   TALEN      Follow-up   TCRα, TCRβ, CD52 knockout                                                 Advanced lymphoid malignancy                    *Ex vivo*           CD19-CAR modified T cells with CAR delivered by lentivirus and TALEN knockout CD52 and TCR to create universal T cells, 15-year follow-up study   Institut de Recherches Internationales Servier                                    U.K., Belgium, France, U.S.A.   NCT02735083   4/12/2016
                                                   Cas9       Follow-up   Disruption of the erythroid enhancer to *BCL11A* gene                     β-thalassemia and severe sickle cell anemia     *Ex vivo*           *Ex vivo-* modified hematopoietic stem cells, 15-year follow-up study                                                                             Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics                       U.S.A., U.K., Germany           NCT04208529   12/23/2019

U.S. clinical trials data base (clinicaltrials.gov) was accessed on 1/1/2020, trials not including interventions using gene editors were excluded. Abbreviations: CAR, chimeric antigen receptor; TCR, T-cell receptor.

Examination of the clinical trials data has shown a rapid increase in registered trials using genome editors, as well as a change in the selected genome editors in the recent years ([Figure 2](#F2){ref-type="fig"}A). The first registered trial is from 2009, and between 2009 and 2015 less than or equal to two trials were registered per year, all of which focused on ZFNs. However, in 2016 and 2017 the number of trials jumped to 10 per year, with a further increase to 13 trials in 2018; 2016 was also the first year TALENs and Cas9 trials were registered, reflecting a change in the genome editing agent as well as number of trials. Separating the data by delivery method also reveals change over time in the selected method ([Figure 2](#F2){ref-type="fig"}B). For example, early trials exclusively used adenovirus-based delivery, whereas later trials also used adeno-associated virus (AAV), polymer-mediated plasmid delivery, and electroporation. Choice of *in vivo* versus *ex vivo* delivery also changed over time ([Figure 2](#F2){ref-type="fig"}C)*. Ex vivo* delivery, where the cells are altered in the lab and then infused into the patient, primarily utilizes electroporation as the methodology, but transduction by adenovirus is also used. *In vivo* delivery has focused on both localized delivery and systemic delivery. Registered clinical trials with localized delivery prior to 2019 were focused on polymer-mediated plasmid delivery of ZFNs, TALENs, or Cas9 to the vagina. However, localized delivery sites are expanding with a new trial in 2019 proposing direct injection into the eye of Cas9 via AAV vector. To date, systemic delivery has been limited to IV-based delivery of AAV using ZFN-mediated addition of a gene to hepatocytes.

![Trends in genome editor use in clinical trials\
Genome editing trials registered in the U.S. clinical trials database by year and selected genome editor (**A**), or delivery method (**B**) and delivery method grouped by *in vivo* or *ex vivo* use (**C**). Some trials did not have a clear delivery methodology (labeled as unknown). These unknown delivery methods are all *ex vivo* delivery making electroporation the most likely method. Data were accessed 1/01/2020.](bsr-40-bsr20200127-g2){#F2}

*Ex vivo* cell alteration and infusion trials {#sec2-1}
---------------------------------------------

Current clinical trials using *ex vivo* alteration by genome editors overwhelmingly focus on the modification of T cells to disrupt gene expression to either treat HIV-1 infection, or to enhance the efficacy of engineered T cells to counter cancer. The earliest gene editing studies have been focused on disruption of the gene encoding CCR5, a major co-receptor that facilities HIV-1 entry into T cells. This idea of gene editing CCR5 for curing or controlling HIV infection in patients was bolstered by the 'Berlin Patient', an HIV-positive patient who was treated for acute myeloid leukemia by bone marrow transplant in 2007. The physicians decided to perform the transplant with bone marrow from a donor who was homozygous for a CCR5 mutation known as CCR5 Δ32. This mutation results in loss of CCR5 expression on the cell surface, and, in this case of the Berlin Patient, resulted in a clinical cure of HIV infection \[[@B18],[@B19]\]. CCR5 was chosen as an early target for gene editing because it has naturally occurring mutations that lead to loss of surface expression without any known severe adverse effects, and the effective loss of CCR5 was demonstrated to cure the patient of HIV. While the Berlin Patient underwent allogenic bone marrow transplant, in patients without leukemia it may be possible to disrupt the *CCR5* gene *ex vivo* and then return the engineered cells to the patients via autologous stem cell transplant. ZFNs to knockout CCR5 in human cells were already under development when the Berlin Patient was treated, and the first clinical trial was initiated in 2009 \[[@B20],[@B21]\]. Additionally, although the majority of HIV therapy trials have focused on ZFNs, CRISPR/Cas9 has also been shown experimentally to provide a functional knockout of CCR5 which conferred resistance to HIV infection \[[@B22],[@B23]\], and the first human clinical trial of Cas9 for CCR5 knockout was registered in 2017.

The use of CRISPR Cas9 in HIV also opens several new possibilities for HIV therapy. While The Berlin Patient was cured of HIV through transplantation with CCR5 Δ32 bone marrow, several other attempts to perform this type of cure have failed and other patients have had viral rebound \[[@B24],[@B25]\]. One possible reason for viral relapse is that there are two main co-receptors used for HIV entry, CCR5 and CXCR4. While most new infections are caused by a CCR5 utilizing variant of HIV, many chronic patients have both CCR5 and CXCR4 utilizing variants \[[@B24]\]. In pre-clinical studies, ZFNs have been developed for CXCR4 and have demonstrated utility together with CCR5-targeting ZFNs \[[@B26]\]. Pre-clinical studies of CRISPR/Cas9-based strategies have also been used to successfully knock out both CCR5 and CXCR4, and this method can be more efficient than ZFNs as only multiple gRNAs, rather than multiple proteins, need to be delivered \[[@B27],[@B28]\]. Cas9 also presents the potential to eradicate HIV-1 reservoirs through the disruption of integrated HIV-1 proviral DNA in a variety of cell types \[[@B25]\]. One *in vivo* study demonstrated that AAV delivery of Cas9 and gRNAs resulted in deletion of a large section of the genome-integrated HIV-1 provirus in a variety of tissues \[[@B29]\]. And finally, recent work demonstrated that a combination of gene editing, using AAV-delivered CRISPR components, with long-acting slow-effective release antiretroviral therapies (LASER ARTs) could clear latent infectious reservoirs of HIV-1 in humanized mice \[[@B30]\]. While CXCR4 targeting, dual targeting of CCR5 and CXCR4 and deletion of HIV provirus have not yet reached the clinical stage, the pre-clinical studies highlight where genome editors may take HIV-1 therapy in the future.

While HIV-1 therapy was the earliest gene editing clinical trial and remains a major focus, many of the recent trials have focused on tailoring T cells for adoptive cell transfer (ACT) for cancer. There are four types of ACT to which gene editing is being applied: general T cells, tumor-infiltrating lymphocytes (TILs), T-cell receptor (TCR) bearing cells, and chimeric antigen receptor (CAR) bearing T cells ([Figure 3](#F3){ref-type="fig"}). The first two types of ACT to which gene editing is being applied, general T cells and TILs, involves the natural, unaltered, T-cell targeting with gene editing to knock out a gene of interest. The second two ACT types, TCR and CAR modified T cells, involve genetically altering T cells via gene transfer in order to direct them to target cells of interest, and then further altered these cells by gene editing. Gene editing is being applied to ACT in several ways: to enhance survival after transfer, increase efficacy, prevent self-targeting, or develop universal T cells.

![Genome editing used to enhance ACT of T cells for cancer therapy\
(**A**) Genome editing (highlighted by green arrows) is being explored to create universal donor T cells to serve as the basis for TCR and CAR T-cell engineering. Genome editing is also being explored to enhance the survival and/or efficacy or prevent self-targeting of both natural (circulating T cells and TILs) and engineered (TCR and CAR) T cells. (**B**) TCR engineered T cells have the addition of a second set of TCR α and TCR β genes (highlighted in red and pink) which are present in addition to the naturally occurring TCR α and TCR β genes (highlighted in blue). (**C**) CAR engineered T cells have a chimeric cell receptor with an scFv composed of variable heavy and light chains (V~H~ and V~L~) of an antibody as the extracellular portion fused to intracellular T-cell signaling domains to cause T-cell activation upon interaction with the targeted cell surface marker. Genome editing is also being applied to circulating T cells collected from a patient's blood (**D**) and to isolated tumor infiltrating lymphocytes (**E**), which utilize the native T-cell targeting to destroy tumor cells. Abbreviation: scFv, single-chain variable fragment.](bsr-40-bsr20200127-g3){#F3}

The earliest clinical trial utilizing CRISPR (NCT02793856) focused on collecting general T cells from peripheral blood and utilizing Cas9 to knock out the programmed cell death protein 1 (*PD-1*) gene. PD-1 is a protein found on the surface of T cells that negatively regulates T-cell activation upon interaction with its ligand, PD-L1. High expression of PD-1 on the T-cell surface accelerates T-cell tolerance and exhaustion, limiting the efficacy of T cells against tumors. The primary safety concern with the first CRISPR trial was that use of general, non-specific T cells, rather than TILs collected directly from the patient's tumors, might lead to a general overactivation of the patient's immune system \[[@B31]\]. While the concern is valid, and toxicity due to anti-PD-1 and anti-PD-L1 therapies is a known issue \[[@B32]\], systemic therapy with PD-1 and PD-L1 blockers has been approved by the U.S. Food and Drug Administration (FDA) for a variety of cancers \[[@B33]\], which the researchers felt mitigated the concern \[[@B31]\]. The data from this first in human CRISPR trial reported thus far indicate no major adverse events; the trial was not designed to examine efficacy, however, so the effectiveness of this therapy is currently unknown \[[@B34],[@B35]\].

One major limitation to the first CRISPR clinical study is that the collected T cells are not enriched for cells likely to respond to the tumor cells. One method around this is the use of TILs collected directly from tumor resections. TIL therapy has a long history of clinical trials in melanoma \[[@B36]\], including long-term robust patient response, and is being developed for other cancers including cervical, ovarian, kidney, gastrointestinal, and head and neck cancers \[[@B37]\]. Two TIL clinical trials to treat gastrointestinal cancer involve the collection of TILs from patient tumors and enhancing their antitumor efficiency through knock out of the gene *Cish*. TILs capable of targeting gastrointestinal cancer cells have been found in patients \[[@B38]\]; however, Cish, a member of the suppressor of cytokine signaling (SOCS) family, has been shown to block the avidity of the TILs and reduce their activity against cancer \[[@B39]\]. In a mouse model, knockout of the *Cish* gene in TILs led to increased expansion and responsiveness, leading to tumor regression \[[@B39]\]. Furthermore, pre-clinical studies of ZFN-mediated knockout of PD-1 in TILs for treatment of melanoma suggest that clinical trials using TILs with gene knockouts will be pursued in the future \[[@B40]\].

While the trials on TILs and general T-cell gene editing focused on modifying naturally targeted T cells, the majority of *ex vivo* gene editing trials focus on using gene editors to enhance TCR and CAR-engineered T cells ([Figure 3](#F3){ref-type="fig"}A--C). Engineering the T-cell recognition through either the addition of a specific TCR or CAR to T cells circumvents several of the issues presented with TILs: first, not all patients have tumor-responsive T cells; second, these cells must be collected from surgical resections of tumors; finally, there is no control over the targeted cancer antigen. TCR-engineered T cells are based on transferring the genes encoding the α and β chains of a TCR specific to an antigen unique to, or overexpressed in, tumor cells into collected T cells that are then re-infused into the patient. In contrast, CARs are artificial chimeric receptors created to target cell surface markers on cancer cells. CARs are artificial receptors consisting of an external single-chain variable fragment (scFv) created from the variable regions of the heavy and light chains of antibodies for target specificity and internal T-cell signaling domains leading to T-cell activation upon scFv binding \[[@B41],[@B42]\]. Similar to TCR engineering, CAR can be transferred in to collected T cells and then re-infused into the patient. TCR and CAR engineered T cells each present unique advantages and challenges that gene editing can address \[[@B43]\]. TCR engineered T cells have some advantages over CAR engineered T cells: the TCR is able to recognize intracellular proteins, including novel tumor antigens created by mutations, whereas CAR recognizes only proteins present on the cell surface \[[@B43]\]. However, the TCR recognizes peptides from intracellular proteins presented on the surface of the tumor cell in the major histocompatibility complex (MHC) class I molecules, and loss or down-regulation of MHC molecules is a major source of tumor escape from immune surveillance which could limit the efficacy of TCR-based therapies \[[@B44]\]. CAR T-cell recognition of target is independent of MHC expression, but limited to cell surface markers, which are commonly present on both diseased and normal cells, which can limit the utility of CAR T-cell therapy \[[@B43]\]. Both TCR and CAR T-based therapy has been pursued independent of gene editing, but gene editing is opening new possibilities for enhancing immune therapy and will be discussed in more detail.

A number of TCRs that mediate T-cell targeting of tumor cells have been identified and tested in clinical trials \[[@B45]\]. One of the most promising of these TCRs is NY-ESO-1 \[[@B46]\]. T cells engineered to express the NY-ESO-1 TCR have been used as effective therapy for melanoma, synovial cell carcinoma, and myeloma \[[@B45]\]. One potential limitation to TCR therapy is the presence of the endogenous TCR α and β chains, which could pair with the engineered TCR α and β chains to create heterologous pairs. These heterologous pairs might reduce efficacy due to their inability to recognize the intended target, and cause toxicity due to recognition of unintended targets \[[@B47]\]. The one registered gene editing trial to date (NCT03399448) which focuses on engineered TCRs uses CRISPR/Cas9 to knockout the endogenous TCR α and β chains (to remove the potential for heterologous TCR pairings) as well as PD-1 (to enhance TCR engineered T-cell efficacy).

The majority of *ex vivo* gene editing trials focus on the enhancement of CAR engineered T-cell therapy. CAR T-cell therapy is the first form of gene transfer therapy to gain FDA approval, with two approved therapeutics, Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta or Axi-Cel) for CD19-positive refractory pre-B cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, respectively \[[@B43],[@B48]\]. While both approved therapeutics target B-cell malignancies, CAR T therapy represents an extremely large clinical trial space, with over 250 clinical trials in a wide variety of cancers currently underway \[[@B43],[@B49]\]. Of these clinical trials, a number of them include gene editors to further enhance the CAR engineered T cells. Delivery of the CAR gene into T cells is mediated by γ retroviral or lentiviral vectors; the advantage of these delivery systems is a high rate of gene transfer and stable expression of the CAR. However, these viral vectors integrate the CAR randomly into the genome, which can lead to varied CAR expression, insertional mutagenesis, overexpression of adjacent genes, and disruption of genes at the site of integration. While evidence of these issues is yet to been seen in CAR therapy \[[@B50]\], insertional oncogenesis and overexpression of adjacent genes have been seen in a human gene therapy trials using these viral vectors \[[@B51]\]. One potential method around this is to direct where the CAR is inserted into the genome. Disruption of the TCR α constant (TRAC) locus has been demonstrated using TALENs, Cas9, and megaTAL Nucleases, with both TALENs and Cas9 being highly effective at disrupting TRAC expression and thereby reducing TCR expression on the T-cell surface \[[@B56]\]. Recently, this ability has been expanded to allow specific insertion of the CAR into the TRAC locus using Cas9 or TALENs \[[@B57]\]. Integration of the CAR into the TRAC locus increased CAR T cell anti-tumor activity in mice models. The insertion of the CAR into the TRAC locus has the advantage of also disrupting the native TCR surface expression, which reduces the likelihood of graft-versus-host disease (GvHD) and increases the safety of allogenic CAR T therapy \[[@B60]\]. This idea forms the basis for the clinical trial NCT03398967, which proposes to integrate two CARs (to CD19 and either CD20 or CD22) into the TRAC locus for allogenic ACT. The created cells will lack native TCR expression, which will facilitate allogenic ACT; and the dual targeting is hoped to prevent the relapse seen in CD19 CAR T therapy, where the cells lose CD19 expression by utilizing two surface targets \[[@B48],[@B61]\].

A number of clinical trials are focused on the creation of universal CAR T cells, through knockout of the TCR through removal of TRAC alone or of the TRAC and TCR β constant (TRBC) loci. Removal of the TCR should prevent the transferred T cells from recognizing host antigens, which leads to GvHD. However, the presence of human leukocyte antigen (HLA) system proteins on the surface of the transplanted T cells, if mismatched with the host, can lead to rapid rejection of the transplanted cells. Some of the studies aim to both prevent GvHD and rapid rejection. For example, the removal of β-2 microglobulin (B2M), which is necessary for HLA expression, in addition to TRAC and TRBC resulting in increased efficacy of CD19 CAR T cells compared with removal of the TCR alone in mice models \[[@B62],[@B63]\]. The combined knockout of the TCR with B2M by Cas9 in CD19 CAR T therapy is currently being tested in clinical trial (NCT03166878).

Another gene commonly targeted for removal by gene editing agents in CAR therapy for leukemia is *CD52*. CD52 is the protein targeted by alemtuzumab, a chemotherapeutic agent commonly used in leukemia treatment, but which can also kill the transplanted CAR T cells. Removal of both the TCR (to prevent GvHD) and CD52 using TALENs allowed generation of allogenic CD19 CAR T cells that could be used in combination with alemtuzumab in a mouse model \[[@B64]\]. The utility of these TALEN edited CD19 CAR T cells is the basis of three currently running clinical trials (NCT02735083, NCT02746952, and NCT02808442). Prior to initiation of these trials, two infants with relapsed refractory CD19^+^ B-cell acute lymphoblastic leukemia were treated with TALEN-mediated CD52 and TCR knockout CD19 CAR T cells in combination with anti-CD52 therapy \[[@B58]\]. Both infants achieved molecular remission and had lasting CD19 CAR T-cell persistence. In addition to removing antigens targeted by chemotherapy agents, the ability to remove genes allows application of CAR T-cell therapy to T-cell malignancies through the removal of the targeted T-cell surface marker. CD7 is highly expressed on a variety of T-cell malignancies, but expression of the CD7 CAR prevented CAR T-cell expansion due to fratricide in culture. CD7 knockout through Cas9 resulted in efficient expansion of CD7 CAR T cells while retaining CD7 selective killing in a mouse model \[[@B65]\], and is the basis of a current clinical trial (NCT03690011).

Another common gene editing approach in CAR T cells is the knockout of PD-1, either alone or in combination with TCR knockout. Selective knockout of PD-1 in the therapeutic T cells may be advantageous over systemic anti-PD-1 therapy, which can have significant immune toxicities \[[@B66]\]. Combination of CAR therapy with PD-1/PD-L1 blockade is currently being examined in clinical trials, and preliminary results from CD19 targeted CAR T-cell therapy has shown limited toxicity and enhanced CAR T-cell survival \[[@B67]\]. The PD1 knockout by Cas9 has been shown to enhance the efficacy of CD19 and mesothelin CAR T cells in mouse models \[[@B70],[@B71]\]. PD1 knockout has also been combined with the gene knockouts designed to create universal CAR T cells \[[@B62],[@B63]\]. Clinical trials using CRISPR/Cas9 editing in CAR T cells are underway, including PD1 knockout in combination with mesothelin CAR T cells without or with TCR knockout (NCT03747965 and NCT03545815, respectively), and with CD123 CAR T cells with CD52 knockout (NCT03190278 and NCT03203369).

Another focus for *ex vivo* gene editing trials is the treatment of two hemoglobinopathies, β-thalassemia and sickle cell disease. While gene therapy has previously been successfully applied to β-thalassemia, through lentiviral transfer of the β-globin gene (HBB) \[[@B72]\], the concern remains that random integration might result in oncogenesis \[[@B73]\]. Gene editing provides an alternative to viral delivery of intact genes for the treatment of β-thalassemia and sickle cell anemia. While a number of studies have focused on utilizing genome editors to facilitate the correction of mutations in HBB, or to aid in site specific incorporation of an intact copy of HBB \[[@B74]\], others have focused on the editing ability alone. It has long been known that mutations resulting in persistence of fetal γ-globin expression (usually silenced at birth) reduce the debilitating effects of mutations in β-globin, including β-thalassemia and sickle cell disease \[[@B79]\]. Genome editing has been utilized to recreate the large deletion which causes Hereditary Persistence of Fetal Hemoglobin (HPFH), and hematopoietic stem cells that were Cas9-edited to create HPFH show increased expression of fetal γ-globin \[[@B80]\]. Other studies have focused on deleting the fetal globin repressor BCL11A, leading to increased fetal γ-globin expression. ZFN, TALEN, and Cas9 have all been applied to BCL11A knockout and ZFN-edited hematopoietic stem cells were able to engraft in mice and express fetal γ-globin \[[@B81],[@B82]\]. Disruption of BCL11A in hematopoietic stem cells via ZFN or Cas9 followed by cell transplantation to treat β-thalassemia or sickle cell disease clinical trials are currently underway (NCT03432364, NCT03653247, NCT03655678, and NCT03745287).

*In vivo* gene editing trials {#sec2-2}
-----------------------------

Clinical trials of genome editors delivered *in vivo* have also been initiated. The trials to date have focused on easily accessible tissues, such as the cervix, eye, and liver. The latter being the most likely place for the delivered editing agent to accumulate. The largest set of *in vivo* genome editing trials has focused on eradication of integrated E6 and E7 HPV genes in cervical cancer. While vaccines are now available for HPV, the vaccines do not provide therapeutic effect for those who have already developed cervical cancer \[[@B83]\]. All of the trials to date have originated in China, starting with a trial in 2016 that proposed the use of ZFNs, but in 2017 both TALEN and Cas9 trials were also registered. These trials take advantage of the easy access to the cervix through the vagina, and in each case the delivery vehicle is a polymer gel suppository, the safety of which was recently tested in animal models \[[@B84]\]. Non-viral delivery of ZFNs, TALENs, or Cas9 targeting the integrated E7 oncogene reduced tumor burden in mouse models \[[@B85]\]. While the clinical trials to date have focused on non-viral delivery, AAV delivery of Cas9 targeted to E6 and E7 has also been shown effective in xenograft models \[[@B88],[@B89]\]. Targeting E6 and E7 with genome editors often directly results in cell death; however, targeting these genes can also increase the sensitivity of tumors to other modes of therapy, including chemotherapy and radiotherapy \[[@B83]\], providing an increased rationale for utilizing these genome editors. One particularly interesting study examined HPV16^+^ patient xenografts of anal cancer in immunodeficient mice followed by Cas9 targeting of E6 and E7 \[[@B88]\]. This work demonstrated a significant reduction in tumor growth in mice \[[@B88]\], suggesting that the therapeutic utility of genome editors for HPV treatment extends beyond cervical cancer.

While the largest set of *in vivo* genome editing trials was focused on treatment of cervical cancer, early use of *in vivo* ZFN gene editors was aimed to treat hemophilia B by replacing disease causing mutations in the *F9* gene, which causes a deficiency of blood coagulation factor IX \[[@B90],[@B91]\]. While the traditional gene editing approach is to replace the damaged gene at its native locus, if transcription from the native locus is too low there may not be a therapeutic effect. To address this issue, a subsequent study utilized AAV vectors to deliver a pair of ZFNs targeting gene replacement constructs at the albumin locus, which functions as a safe harbor locus with high transcriptional activity \[[@B92]\]. As the delivery of two targeted ZFNs and a cDNA requires three AAVs to hit the same cell after IV injection, utilizing a highly expressed 'safe site' in the genome is more likely to result in therapeutic levels of protein expression. A commonly used safe site for gene integration is the adeno-associated virus integration site 1 (AAVS1), which can also be targeted for gene integration by ZFNs \[[@B93],[@B94]\].

Another commonly used integration site is the albumin locus, which is an especially attractive site for genome integration of secreted proteins. Exon 1 of the albumin gene encodes a secreted peptide that is cleaved from the final albumin product, so the addition of the cDNA with a splice acceptor site into intron 1 allows the creation of a new protein combining the secretory peptide and the protein of interest \[[@B92]\]. The initial work on this system showed the ability insert the cDNA and a number of proteins including Factor IX (hemophilia B), Factor VIII (hemophilia A), α-Galoactosidase A (Fabry Disease), α-[l]{.smallcaps}-Iduronidase (Hurler Syndrome, a.k.a. mucopolysaccharidosis type I (MPS I)), Iduronate-2 Sulfatase (Hunter Syndrome, a.k.a. mucopolysaccharidosis type II (MPS II)), and Acid β-Glucosidase (Gaucher Disease) \[[@B92]\]. Treatment of animal models of hemophilia A and B resulted in significant improvement in blood clotting, and intervention in MPS I and II prevented or reduced neurocognitive deficit in young animals \[[@B92],[@B95],[@B96]\]. Of these initial gene sets, replacement of Factor IX, α-[l]{.smallcaps}-Iduronidase, and Iduronate-2 sulfatase for hemophilia B, MPS I and II have advanced to clinical trials. The early stage results from the MPS II study suggested the treatments were safe, but also showed very low rate of editing events and inconclusive therapeutic efficacy in the low and medium dose patients \[[@B97]\]. Patient treatments are expected to continue through 2019, but future trials will likely focus on second-generation ZFNs that may have increased activity in human liver cells \[[@B97]\].

Beyond the use of ZFNs, the first AAV Cas9 trial was registered in 2019. The trial utilizes AAV to deliver Cas9 to the eye as a cure for Leber congenital amaurosis type 10 (LCA10). LCA10 is an ideal candidate for Cas9 therapy, as the most common LCA10 causing mutation occurs within an intron of the *CEP290* gene, creating a novel splice site which alters the mRNA to create a premature stop codon \[[@B98]\]. The treatment utilizes two sgRNAs which together mediate loss of part of the intron or inversion of this partial intron, either of which results in normal expression of CEP290 protein in patient cells. Furthermore, the eye is readily accessible, and subretinal injection in mice and primates resulted in sustained gene editing at a level expected to be therapeutic in humans \[[@B98]\].

Clinical trials with inactive nucleases for transcriptional activation {#sec2-3}
----------------------------------------------------------------------

Another interesting aspect is the use of ZFNs, TALENs, and Cas9 with inactive or absent nuclease function to allow semi-specific transcriptional activation or suppression. The advantage of this approach is that sequence specificity can be retained for targeted gene activation or inactivation without causing permanent alteration to the genome. From a clinical standpoint, this can reduce the concern about creating unwanted mutations as the DNA remains intact while still allowing alteration in gene expression. While the initial studies were limited to Zinc Finger Protein (ZFP)-based transcription factors for activation of VEGF expression ([Table 2](#T2){ref-type="table"}), these studies suggest a path forward for more recent transcriptional activators and epigenome editors, based on deactivated Cas9 (dCas9), ZFPs, and transcription activator-like effector proteins (TALEs), which can be used to not only modulate transcription temporarily but also alter genome structure through methylation and acetylation to allow permanent changes in gene transcription \[[@B11],[@B99],[@B100]\]. Later in this review we will discuss the recent technological advances regarding CRISPR-based control of gene expression and the epigenome in greater detail.

###### Clinical interventions using inactive genome editors as transcription factors

  Vector          Transcription factor type   Phase   Target Gene and effect        Disease                                                                 *Ex vivo/in vivo*   Intervention                       Sponsor organization                                Country   NCT number    Date posted
  --------------- --------------------------- ------- ----------------------------- ----------------------------------------------------------------------- ------------------- ---------------------------------- --------------------------------------------------- --------- ------------- -------------
  Naked plasmid   ZFP TF                      I       VEGF-A increased expression   Artheriosclerosis and intermittent claudication (lower limb ischemia)   *In vivo*           Injection into the leg             National Heart, Lung, and Blood Institute (NHLBI)   U.S.A.    NCT00080392   3/30/2004
                  ZFP TF                      I       VEGF increased expression     Diabetic limb neuropathy                                                *In vivo*           Injection into the leg             Sangamo Therapeutics                                U.S.A.    NCT00110500   5/10/2005
                  ZFP TF                      II      VEGF increased expression     Diabetes type 1 and 2, diabetic limb neuropathy                         *In vivo*           Injection into the leg             Sangamo Therapeutics                                U.S.A.    NCT00406458   12/4/2006
                  ZFP TF                      II      VEGF increased expression     Diabetes type 1 and 2, diabetic limb neuropathy                         *In vivo*           Injection into the leg             Sangamo Therapeutics                                U.S.A.    NCT00476931   5/22/2007
                  ZFP TF                      II      VEGF increased expression     Diabetes type 1 and 2, diabetic limb neuropathy                         *In vivo*           Injection into the leg             Sangamo Therapeutics                                U.S.A.    NCT00665145   4/23/2008
                  ZFP TF                      II      VEGF increased expression     Amyotrophic lateral sclerosis                                           *In vivo*           Injection into neck, arm, or leg   Sangamo Therapeutics                                U.S.A.    NCT00748501   9/8/2008
                  ZFP TF                      II      VEGF increased expression     Diabetes type 1 and 2, diabetic limb neuropathy                         *In vivo*           Injection into the leg             Sangamo Therapeutics                                U.S.A.    NCT01079325   3/3/2010

U.S. clinical trials data base (clinicaltrials.gov) was accessed on 1/1/2020.

Looking forward: upcoming areas for gene editor clinical trials {#sec2-4}
---------------------------------------------------------------

The genome editing landscape is moving very quickly and a number of potential therapies beyond those currently in clinical trials are rapidly approaching the clinical trial space. Many pharmaceutical companies put out regular updates on their development pipelines, giving insight into the likely coming trials. The majority of the anticipated *ex vivo* trials revolves around CAR T therapy and hemoglobinopathies (β-thalassemia and sickle cell disease) \[[@B101]\]. Beyond these anticipated trials, another likely area of *ex vivo* clinical genome editor use are the monogenic primary immunodeficiencies (PIDs). Similar to the *in vivo* ZFN trials, treatment of the PIDs would require the insertion of a correct gene (or cDNA) copy. However, treatment of these PIDs is in some way ideal for genome editing, as the standard treatment is typically hematopoietic stem cell transplant, meaning the cells can be modified *ex vivo* which removes the *in vivo* delivery problem encountered with *in vivo* AAV trials \[[@B97]\]. Furthermore, these diseases are severe enough that they are already the subject of gene therapy trials \[[@B102]\]. Pre-clinical studies using genome editors and donor DNA have been demonstrated for three PIDs; X-linked severe combined immunodeficiency (SCID-X1) \[[@B103]\], chronic granulomatous disease (CGD) \[[@B106]\], and Wiskott--Aldrich syndrome (WAS) \[[@B112]\]. Pre-clinical studies in SCID-X1 have focused on addition of a functional copy of interleukin-2 receptor subunit γ (IL2RG) into the AAV1 safe harbor site or, more commonly, into native gene site \[[@B103]\]. These studies were able to demonstrate functional gene expression and long-term engraftment in immunodeficient mouse models utilizing ZFNs \[[@B103],[@B105]\] and Cas9 \[[@B104]\] genome editing followed by integration of the provided therapeutic gene copy in SCID-X1 patient cells. Similar to the studies in SCID-X1, genome editing followed by integration of provided sequence to insert functional gene copy has been demonstrated in CGD patient cells and resulted in long-term engraftment in immunodeficient mice using TALENs \[[@B108]\], ZFNs \[[@B107],[@B108],[@B110]\], and Cas9 \[[@B106],[@B109]\], laying the groundwork for clinical trials in this space.

Beyond *ex vivo* trials, there are some promising advances in *in vivo* treatment of readily accessible tissues, such as the eye or ear. The eye is an attractive site for genome editing as direct access and self-contained nature of the eye reduces systemic effects. AAVs for delivery to the retina have already been identified and tested clinically, with one AAV-based gene therapy already approved and tissue specific promoters are also known which can further limit expression to the cells of interest \[[@B113],[@B114]\]. The first Cas9 clinical trial for blindness, treatment of LCA10, has already been registered (NCT03872479) and was discussed in the current trials section. Also under development is Cas9 therapy involving the knockout of the endogenous gene copies and replacement with a functional copy for autosomal dominant cone--rod dystrophy (CORD6)-mediated blindness which has progressed to use in non-human primates \[[@B115]\]. Beyond the initiated LCA10 trial and CORD6 experiments, CRISPR-based therapeutics are being developed for a range of other inherited retinal disorders and multifactorial retinal diseases which has been reviewed elsewhere \[[@B116],[@B117]\]. In addition to the eye, the ear is another site that also allows ready access for genome editing. While the studies in the ear have not progressed as far as the eye, correction of the *USH2A* gene responsible for both visual and hearing impairment in Usher syndrome has been shown in patient cells utilizing Cas9 and an DNA template \[[@B118]\]. Beyond *in vitro* cell manipulation, Cas9 nickases with paired sgRNAs in combination with an oligonucleotide donor template editing of zygotes were able to prevent age-related hearing loss in an mouse model \[[@B119]\]. Finally, Cas9 was used to selectively disrupt the mutant allele of Tmc1 (transmembrane channel-like gene family 1) associated with autosomal dominant hearing loss while sparing the wild-type allele and preventing progressive hearing loss \[[@B120],[@B121]\].

In addition to easily accessible sites, liver targeted therapeutics are under development due to accumulation in liver of intravenously injected materials \[[@B101]\]. Several groups have published on the potential to treat α-1 Antitrypsin Deficiency (AATD) utilizing Cas9. α-1 antitrypsin (AAT) is secreted by the liver, and if the mutant allele is present, the protein aggregates in hepatocytes causing liver fibrosis, cirrhosis, and cancer and the reduction in circulating AAT also results in emphysema and Chronic Obstructive Pulmonary Disease (COPD) in the lungs. Cas9 has been used to knockout the mutant *AAT* gene or to knockin the normal gene in to a safe harbor site in mouse models \[[@B122]\]. Research has shown that dual delivery of both Cas9 targeted to ATT in combination with a donor template will knockout the mutant allele and integrate the wild-type allele, leading to expression of the wild-type AAT in mouse models \[[@B124],[@B125]\]. In addition to therapeutics development to treat AATD in liver, non-viral, lipid nanoparticle (LNP) delivery of Cas9 facilitating hepatocyte selective targeting for the editing of mouse liver transthyretin gene, the mouse homolog of the human gene associated with Transthyretin Amyloidosis, which is caused by a buildup of misfolded transthyretin protein \[[@B126]\]. The *in vivo* delivery resulted in a greater than 97% reduction in serum and liver protein levels and the reduction persisted for 12 months \[[@B126]\]. The authors of this paper, also state this methodology can be applied to Hepatitis B treatment \[[@B101]\]. Hepatitis B treatment by Cas9 and other genome editors, as well as treatment for other oncolytic viruses, has been reviewed extensively elsewhere \[[@B127]\].

While the previously discussed potential disease targets focus on diseases in tissues already under trial for genome editors, there are also development pipelines for new tissues and diseases, including Cystic Fibrosis (CF), Duchenne muscular dystrophy (DMD) \[[@B101]\], and spinal cord injuries \[[@B130]\]. CF was the target of the earliest gene therapy trials as well as many ongoing gene therapy trials, one reason for this is the lungs can be readily targeted by inhalation \[[@B131],[@B132]\]. However, to date, the efficacy has been too low in these trials for therapeutic effect \[[@B131],[@B132]\]. Genome editors present a new possibility for therapeutic treatment of CF, although the low efficacy with gene therapy delivery agents studied to date may also apply to the delivery of genome editors. Repair of CF mutations has been demonstrated with ZFNs and Cas9 *in vitro* as well as in patient induced pluripotent stem cells \[[@B133]\], although testing in animal models has not yet been performed. CF is an interesting and challenging disease as the CF transmembrane conductance regulator (CTFR) gene is very large and there are numerous mutations associated with the disease. Several gene editing strategies have been used to treat CF including Cas9 targeted removal of mutations that lead to nonfunctional protein splicing \[[@B135]\], ZFNs and Cas9 used to repair the ΔF508 mutation \[[@B134],[@B137]\], ZFNs used for the targeted addition of exons 11--27 of the CTFR gene into exon 11 as a functional gene correction \[[@B136]\], and Cas9 utilized to add a functional copy of the CTFR gene into an AAVS1 safe site \[[@B133]\].

Similar to CF, the gene encoding dystrophin, called DMD, is very large and there are numerous documented mutations along the entire gene that can cause DMD. The *DMD* gene is an interesting target for genome editing because a wide range of edit types can act as a functional cure including exon deletion, exon skipping, exon reframing, and exon knockin, depending on the specific disease causing mutation present \[[@B141]\]. While the use of Cas9 for DMD has been reviewed elsewhere \[[@B141]\], there are a few studies in this field worth highlighting specifically. The first is the use of Cas9 to correct the ΔE50-MD canine model of DMD, the present study examined both localized muscle delivery and systemic delivery via AAV. Systemic delivery resulted in expression of dystrophin in multiple muscles, including cardiac muscle at rates near normal at 8 weeks post-systemic delivery \[[@B142]\]. While longer term studies are needed in larger animal models, such as canines, a long-term study was recently completed in a mouse model of DMD. The present study utilized systemic AAV delivery of Cas9 in neonatal mice and found a single dose administration resulted in sustained editing and dystrophin protein expression 1 year after treatment \[[@B143]\].

Germline editing and CRISPR babies {#sec2-5}
----------------------------------

The rapidly advancing CRISPR toolkit holds many promising developments toward advancement of clinical medicine, although there are several safety and ethical concerns still to be addressed. One of the areas of greatest concern is germline editing, which creates a heritable alteration in the genome \[[@B144],[@B145]\]. While an in-depth discussion of the ethical concerns and governmental regulatory concerns raised by germline editing are beyond the scope of this review, the actions in this area have the potential for far reaching effects in clinical genome editing and public image of these technologies \[[@B145]\]. We have therefore provided a brief overview of the technology as used in research and in humans \[[@B146]\].

Cas9 editing of zygotes has been applied to DMD treatment in a mouse model, creating a permanent and potentially inheritable change in the genome \[[@B147]\]. The ability to edit zygotes provides a pathway for eliminating fatal or debilitating monogenetic diseases and could act as a compliment to preimplantation genetic diagnosis \[[@B148],[@B149]\]. This research has gone beyond animal models and editing of human zygotes has also been performed utilizing both non-viable and potentially viable embryos \[[@B146],[@B150]\]. While the researchers publishing these embryo studies highlighted areas of concern as well as promise, such as the need for increased fidelity, specificity, and reproducibility, more recently, CRISPR edited embryos were implanted and resulted in the birth of twins in China \[[@B149],[@B154]\]. While it remains unclear if and exactly how the babies' genes were modified, there has been a flurry of debate regarding germline editing \[[@B149],[@B154],[@B155]\]. This event has created a push for a moratorium on editing human embryos and the World Health Organization announced the establishment of a committee to devise guidelines for Human Gene Editing \[[@B149]\].

Issues limiting *in vivo* clinical use of CRISPR {#sec3}
================================================

While clinical trials have already begun, both *ex vivo* and *in vivo* in humans, there are still some issues that may limit the clinical use of CRISPR *in vivo.* The limiting issue which has received the most attention is the delivery problem: how do we accurately deliver CRISPR, control its activity, and limit off-target events \[[@B156]\]? For example, while AAV delivery is advantageous for gene therapy as it provides the possibility of long-term expression, this may lead to undesirable effects as the CRISPR enzyme would be expressed indefinitely. Non-viral delivery may allow temporal control of CRISPR activity, but the efficacy has traditionally been lower than viral delivery, although recent work with LNPs shows promise for highly efficient non-viral vectors \[[@B126]\]. Due to the diversity of delivery options; CRISPR Cas9 can be delivered as DNA, RNA, or ribonucleoprotein (RNP), a wide variety of delivery vehicles and methods have been developed and several reviews have focused on the methods to achieve delivery with both viral and non-viral vectors \[[@B17],[@B157]\]. Beyond delivery to cells in general, the specificity of delivery is also important as in some cases a specific organ or cell type must be targeted. To date, most *in vivo* clinical trials have focused target tissues with direct access, such as the cervix or eye, or alterations in liver. As the field expands to more disease targets, the ability to target the therapy, either through controlled, tissue-specific expression of Cas9, or cell-specific targeting will become more important. Other limitations to *in vivo* delivery, which have received less attention that the delivery issue, are the detection and consequences of off-target effects, and immunogenicity of CRISPR therapies.

CRISPR immunogenicity {#sec3-1}
---------------------

*In vivo* delivery of CRISPR, both Cas9 and other CRISPR systems, can be immunogenic through three main pathways; innate immunity, humoral immunity, or cellular immunity, illustrated in [Figure 4](#F4){ref-type="fig"} \[[@B158]\]. The innate immune system utilizes pattern recognition receptors to recognize conserved features in microbes, including the recognition of foreign nucleic acids \[[@B159]\]. This raises the possibility that mRNA or DNA encoding CRISPR or the gRNA could be recognized. Studies using *in vitro*-transcribed gRNA have been demonstrated to trigger the innate immune response in both human and mouse cells triggering interferon response and cell death \[[@B160],[@B161]\]. This response could be tempered through the use of chemically synthesized gRNAs or through chemical modification of the *in vitro*-transcribed gRNAs \[[@B160],[@B161]\]. While these studies show proof-of-principle, further studies are needed to identify the best method to avoid the innate immune response to both the gRNA, mRNA, and DNA delivery.

![Mechanisms of Cas9 immunity seen in experimental studies\
Innate immunity is mediated by pattern recognition receptors present on the cell surface (shown in blue), in the endocytic vesicles (shown in green) and cytoplasm (shown in red) of phagocytic cells. Humoral immunity is mediated by antibodies which can neutralize Cas9 protein or delivery vehicles. Both IgG and IgM antibodies have been seen to Cas9 exposure. Cellular immunity is mediated by display of peptides from intracellular proteins on cell surface receptors that can be recognized by cytotoxic T cells mediating killing of Cas9 expressing cells.](bsr-40-bsr20200127-g4){#F4}

Beyond innate immunity, antibodies to *Staphylococcus aureus* Cas9 (SaCas9) and *Streptococcus pyogenes* Cas9 (SpCas9) have been found in human serum samples, suggesting a pre-existing immunity to Cas9 in a portion of the human population due to prior exposure to the two most currently used Cas9 sources, *S. aureus* and *S. pyogenes* \[[@B162],[@B163]\]. These two studies found very different portions of the population to have preexisting antibodies, 10 or 78% to SaCas9 and 2.5 or 58% to SpCas9 \[[@B162],[@B163]\], suggesting some variability either in the testing or populations. Despite these differences, it is clear that a portion of the human population has pre-existing antibodies to the two most commonly used Cas9 enzymes, which could affect the use of these Cas9 molecules *in vivo*. Furthermore, studies in animal models have shown that delivery of SaCas9 by AAV results in the development of anti-SaCas9 antibodies in adult mice after systemic delivery and in non-human primates after injection into the eye \[[@B115],[@B143]\]. Similar to the findings with SaCas9 by AAV, systemic delivery of SpCas9 by adenovirus also resulted in development of anti-SpCas9 antibodies in adult mice \[[@B164]\]. The age of the animal appears to be important in the immune response development as systemic injection of neonatal mice with AAV-SaCas9 did not result in antibody development \[[@B143]\]. While the development of antibodies to Cas9 may not be problematic for single dose therapy with Cas9, it could prevent repeated use. As both pre-existing and developed immunity can occur, these factors may need to be monitored during clinical development of CRISPR therapeutics.

In addition to both innate immunity and humoral immunity, cellular immunity mediated by cytotoxic T cells can also be directed against Cas9-expressing cells. Examination of human blood samples has shown the presence of reactive T cells to both SaCas9 and SpCas9, with the percentage of responding population being 78% to SaCas9 and 67 or 96% to SpCas9, depending on the study \[[@B162],[@B165]\]. Similar to the humoral immunity studies, there is variability in the percentage of responding humans, but it is clear that many people may have cells capable of killing Cas9 transfected cells *in vivo*. In addition, animal studies have shown the development of cellular immunity to Cas9 after AAV delivery of SaCas9 and adenoviral delivery of SpCas9 in mouse models and AAV delivery of SaCas9 in non-human primates \[[@B115],[@B143],[@B164]\]. As seen with antibody development, the age of the animal appears to be important, as systemic delivery of AAV-SaCas9 to neonatal mice did not cause the development of a reactive T-cell response \[[@B143]\]. The development of a T-cell response could be problematic, as it could result in the destruction of Cas9 expressing cells *in vivo*, abrogating the therapeutic effect and potentially result in the therapy exacerbating a condition through eliminating the population of cells targeted for editing. It is possible that this effect could be mediated by immune suppression, however this would not be ideal for long-term treatment, making controlled temporal presence of Cas9 important to prevent adverse immune effects.

The studies to date have shown that age may be an important mediator of the immune response. In addition to age, it is likely that the delivery vector will have a strong effect on the immunological response. In animal models, the delivery of Cas9 with adenoviral vectors, which are highly immunogenic, resulted in decrease in Cas9 expression overtime, no therapeutic effect, inflammation, and hepatocellular toxicity. In comparison, delivery of Cas9 by plasmid resulted in lower gene correction but therapeutic effect suggesting edited hepatocyte survival \[[@B158]\]. It is therefore important to determine and control the immune response to both Cas9 and the delivery vehicle for efficacious editing. One possible method to reduce the immunogenicity of Cas9 is the identify the epitopes leading to immune stimulation and engineer the Cas9 protein to create a low immunogenicity Cas9. Preliminary studies in this area were able to identify the reactive residues and alteration of these residues did not abrogate SpCas9 editing \[[@B164]\], suggesting the potential to reduce the immunogenicity profile of Cas9 and enhance its therapeutic use \[[@B158]\].

Off-target effects {#sec3-2}
------------------

An ideal gene editor would exhibit perfect specificity for the target sequence and cause no mutations to any other region of the genome. Unfortunately, CRISPR/Cas-based editors (and other editors, such as ZFNs and TALENs) rarely achieve such a high standard. Off-target effects primarily arise from the sgRNA seed sequence or PAM sequences binding with sequence mismatches (1--5 bps have been shown to be tolerated) but can also be influenced by cell type and the DNA repair pathways in a particular cell type. The reader is referred to Zhang et al. \[[@B166]\] for a more thorough review of the mechanisms of CRISPR off-target effects. Off-target effects were postulated early in the development of gene editors and recent advances have increased the sensitivity for detection of these effects. As a result, off-target effects have been shown in virtually all systems studied.

The presence of off-target effects does not necessarily prevent gene editing tools from succeeding in clinical applications. Off-target modifications could be tolerated for many treatments if they were random, showing no sequence bias, and the levels were at or below the random mutation frequencies. Additionally, while off-target effects may have significant consequences in specific cell types, like stem cells or neurons, they could be more tolerable in cells that are fully differentiated or those with short replicative lifespans. Ultimately, the treatment risk must be weighed with disease prognosis and the potential benefit. Currently accepted clinical treatment methods for many diseases carry with them high risk including mutagenesis (e.g., cisplatin for cancer chemotherapy) \[[@B167]\]. High risk of off-target modifications could be accepted for difficult to treat diseases especially where the overall prognosis is poor, provided the possible mutation risks were known.

Strategies for optimizing CRISPR specificity through improved design have resulted in software tools for predicting off-target sites and probabilities ranging in complexity from threshold-based to machine learning-enabled. Assays for detecting CRISPR off-target mutations have traditionally attempted to identify the double stranded breaks created when Cas9 cleaves the genome with a combination of DNA sequencing and bioinformatics. The assays vary in their approach and can suffer substantial bias due to PCR amplification. Approaches for predicting and detecting CRISPR off-target effects developed prior to 2015 are adequately reviewed in Zhang et al. \[[@B166]\]. Most recently this topic has been updated and expanded upon to include developments up through 2018 in a review by Gkazi \[[@B168]\] which presents a concise summary of tools for quantifying off target modification from CRISPR/Cas9 in three categories, *in silico* (prediction), *in vitro*, and *in vivo* assays including advantages and disadvantages to each method*.* To avoid redundancy with these reviews, we limit our discussion here to several promising, newly emergent tools with potential for or direct application for assaying off-target effects in the clinic and refer the reader to Gkazi \[[@B168]\] for information on additional tools and the historical evolution.

One area of interest in off-target discovery are methods that can bridge both *in vitro* and *in vivo* gap in off-target detection. Joung et al. have demonstrated a pipeline that bridges *in vitro* and *in vivo* to enable improved nuclease-based therapeutic strategies in a recent publication \[[@B169]\]. Their system, coined Verification of In Vivo Off-targets or VIVO, invokes a two-staged approach where an initial 'discovery' step is performed *in vitro* to identify a large, inclusive set of potential off-target cleavage sites using Circularization for *In vitro* Reporting of CLeavage Effects (CIRCLE-seq). This initial step is followed by an *in vivo* confirmation step that identifies indel mutations in the potential set of sites. This pipeline is advantageous for examining the genome-wide specificities of CRISPR/Cas editors and identifying off-target effects. Although, not experimentally demonstrated in this initial publication, the approach is believed to be generalizable to non-CRISPR approaches and non-mammalian organisms (Supplementary discussion, \[[@B169]\]).

Corn et al. recently reported a new assay, Discovery of In Situ Cas Off-targets and VERification by sequencing (DISCOVER-seq), for detecting off-target modifications to the genome \[[@B170]\]. DISCOVER-seq operates differently than other off-target detection assays in that it monitors a protein involved in DNA repair, MRE11, to identify where genome edits have occurred rather than the double-stranded break itself. The use of a repair factor protein that is specifically and avidly recruited to a DSB site only during active DNA repair leads to a significant reduction in false-positives over prior methods like ChIP-seq that utilize Cas9 binding as a basis for detection. Importantly, MRE11 is broadly conserved across multiple species and expressed in many cell types. The method has been shown to be insensitive to differences in guide RNA formats and Cas enzyme orthologs. Together these features point to the potential of DISCOVER-seq to be a universal detection platform for identifying off-target mutations *in vitro* and *in vivo*.

Typically, assays for CRISPR/Cas genome edits are accomplished using a variety of targeted PCR amplification followed by next-generation sequencing or next-generation sequencing alone. These assays can be extremely sensitive to small edits such as indels, but inherently insensitive to detection of structural variations including large deletions, translocations, and inversions. Unfortunately, the potential for structural rearrangements are important to measure as chromosome rearrangements can cause alterations in gene expression leading to clinical symptoms or even the development of cancer \[[@B171],[@B172]\]. Additionally, understanding the potential for structural alterations in chromosomes is required both for FDA approval and to the development of safe genome editors for clinical use. Recently, the Uni-directional Targeted Sequencing (UDiTaS) method was shown to successfully measure structural changes and indel events in one reaction \[[@B173]\]. The basis for the method is a custom Tn5 transposon, a unique molecule identifier (UMI) barcode, and a pooling barcode which are assembled and used to tagment genomic DNA. Following amplification of target regions, two rounds of PCR are performed (one using the target primer and the second creating the Illumina sequencing library). The method was shown to be highly linear and sensitive, though it could be limited by bias during the amplification. While the UDiTaS method is designed for use *in vitro*, the ability to look at specific cell types, including primary cells, can define specific large and small genome alterations to monitor in *in vivo* studies and can provide necessary supplemental information on large-scale genomic alterations caused by genome editors.

Similarly, CHAMP (Chip-Hybridization Association Mapping Platform), is an *in vitro* method that has been shown success profiling off-target CRIPSR-Cas binding on synthetic and importantly human genomic DNA \[[@B174]\]. CHAMP utilizes a Mi-Seq flow cell which following DNA sequencing is repurposed for use as a spatially addressable platform containing a library known (sequenced) DNA oligomers that can bind to Cas proteins. In combination with fluorescent reporters on the DNA and the Cas protein and high throughput total internal reflection fluorescence microscopy (TIRFm), each oligo on the chip is read out and the presence of both fluorescent labels indicates that DNA sequence can bind the protein. This method can thus provide quantitative profiling of off-target binding sites in the genomes of induvial patients in the clinic and with future development could also assay target cleavage in addition to binding.

Beyond off-target effects in CRISPR editing and DNA interaction, recent research has found unanticipated effects in protein expression and function after attempted CRISPR gene knockouts \[[@B175]\]. Combined RNA sequencing and triple-stage mass spectrometry was utilized to examine the protein expression of 193 DNA verified CRISPR-induced frameshift deletions and demonstrated protein expression in one third of the targets. Closer examination found the proteins were either N-terminally truncated or the product of skipping the editing exon, creating a different protein isoform. Detailed analysis of three of the truncated proteins found partial preservation of protein function. Additionally, recent studies have demonstrated that the tumor suppressor p53 can inhibit CRISPR engineering in human cells by causing toxicity and cell death as a result of DSB formation \[[@B176],[@B177]\]. The inhibition of CRISPR activity by p53 is particularly concerning as this can promote selection of p53-defective cells with increased tumorigenic potential. Taken together, these studies and other studies of off-target effects reviewed elsewhere highlight the need to understand the biological effects of CRISPR use at the DNA, RNA, and protein levels to prevent unintended effects of CRISPR clinical use of current gene editors and the coming gene editing technologies.

Coming solutions and novel gene editing technologies {#sec4}
====================================================

Having surveyed the landscape of current CRISPR clinical trials, it is important to look forward to anticipate which of the novel CRISPR-based technologies currently in the pipeline are likely to be impactful in the clinic in the near future. In the following sections of this review, we identify and discuss a few areas of focus for future research that will likely have significant clinical impact.

Hyperaccurate CRISPR systems {#sec4-1}
----------------------------

As previously discussed, off-target effects of CRISPR systems are caused by a range of factors, including levels of the CRISPR complex, sgRNA sequence, PAM sequence, and target genome structure/state \[[@B166],[@B178],[@B179]\]. We will discuss efforts to reduce off-target effects by addressing a number of these factors to generate hyperaccurate CRISPR systems ([Figure 5](#F5){ref-type="fig"}).

![Engineering hyperaccurate CRISPR systems\
Several approaches have been used to improve the function of Cas9 proteins and reduce off-target effects. Cas9 function has been modified through the rational design and engineering of a higher fidelity nuclease, modifying the sgRNA for increased stability, directed evolution toward hyperaccuracy, or fusing Cas9 with programmable DNA-binding domains.](bsr-40-bsr20200127-g5){#F5}

When the domain structure and function of an enzyme is known, rational design can be an effective and inexpensive way to rapidly produce high-efficiency alternatives to the canonical protein. With SpCas9, a number of studies have elucidated the structure--function relationships within the protein, opening up the door for mutation by rational design \[[@B180]\]. Enhanced SpCas9 (eSpCas9) is an SpCas9 variant which neutralizes the positive charge of a non-target strand groove located between the HNH (Histidine Asparagine Histidine), RuvC, and PAM-interacting domains in SpCas9. This decreased non-target strand binding, likely allows for rehybridization between the target and non-target DNA strands, which preferentially prevents sgRNA--DNA hybridization at weaker, non-specific interactions \[[@B185]\]. Another example is SpCas9--HF1, which was designed by mutating four residues that are known to be involved in formation of non-specific DNA contacts. This resulted in a form of SpCas9 that retained over 85% of wild-type activity, but almost eliminated off-target effects \[[@B186]\]. In yet another study, the Doudna group demonstrate that a domain in SpCas9 of previously unknown function, REC3, binds to the RNA--DNA duplex, and enables the docking of the HNH nuclease domain at the active site. They also show that both eSpCas9 and SpCas9-HF1 contain mutations in the REC3 domain that block the HNH nuclease domain in the inactive state (also called the 'conformational checkpoint') when bound to mismatched targets. This led them to rationally design a new hyperaccurate SpCas9, called HypaCas9, with mutations in this same REC3 domain that trigger this conformational checkpoint (with the help of another domain, REC2) \[[@B187]\]. These studies demonstrate the usefulness of rational design experiments, where a few targeted mutations can yield significant gains in terms of specificity.

A limitation of rational design however is that, by definition, it is limited by what we know about the target protein, making it potentially limited in scope and inherently biased. The larger scale unbiased alternative to rational design is directed evolution which, while being a lot more resource-intensive and having a smaller rate of success, can yield novel and unexpected variants of a protein. For example, Casini et al. targeted the same domain as the Doudna group, REC3, for generating a hyperaccurate version of SpCas9, but instead of choosing residues to mutate based on known structure, they performed random mutagenesis over this domain and set up a large-scale screen in yeast. Ultimately, they combined four beneficial mutations to create evoCas9, which they show has superior activity and specificity to both wild-type and rationally designed Cas9 (eSpCas9 and SpCas9-HF1) \[[@B188]\]. Another group set up a one-step screen in *Escherichia coli* by introducing a target gene from the human genome (EMX1) into the *E. coli* genome, a mismatched version of the target on a plasmid encoding a toxin, a mismatched sgRNA to EMX1 and a library of SpCas9 mutants. This allowed for an elegant method to select SpCas9 mutants that caused cleavage of the toxin plasmid with the mismatched EMX1 (allowing for survival), but not the EMX1 in the *E. coli* genome (which would cleave the genomic DNA and cause cell death). Through this method, the authors identified a number of mutations not overlapping with any previously identified Cas9 variant and named their best mutant Sniper-Cas9 \[[@B157]\]. A similar method in *E. coli* used an on-target sequence on a toxin plasmid and an off-target sequence on an antibiotic resistance-containing plasmid, with three different human genes, including EMX1. The authors were specifically screening for Cas9 that retained activity and specificity in the context of the RNP form, which is the form with the most precise dose control for introduction of CRISPR components in the context of a therapy or clinical trial \[[@B189]\]. This revealed high-fidelity (HiFi) Cas9, containing a single point mutation (R691A) which the authors show resulted in a variant with high efficiency and specificity when delivered as an RNP in human CD34^+^ hematopoietic stem cells, compared with other high-fidelity Cas9 variants discussed here \[[@B189]\].

Phage-assisted continuous evolution (PACE) with three different PAM sequences on independent plasmids has also been used to expand the PAM specificity of SpCas9. The result, xCas9, harbors mutations near the DNA--sgRNA interface, and recognizes a wider range of PAMs while surprisingly also having decreased off-target effects compared with wild-type SpCas9 \[[@B190]\]. This result shows that directed evolution can expand the PAM specificity without sacrificing target specificity, suggesting that there are still many improvements to CRISPR systems that can be explored which we may not intuitively deduct. Methodically designed directed evolution, as exemplified in the studies above, are likely to be a critical component of designing increasingly efficient and accurate variants of CRISPR components, including other Cas proteins such as SaCas9 and Cas12. Each new study discussed here demonstrates that their version of Cas9 has the highest activity and accuracy compared with its predecessors, which is encouraging in terms of achieving a safe and accurate version of Cas9 that can reliably be used as a therapeutic. However, it is important to remember that there might be cell type- and delivery method-specific differences that can affect specificity and no comprehensive study comparing all of the Cas9 variants across all cell types and deliver methods has been performed. Therefore, each of these variants need to be individually tested for each desired application.

An alternative to introducing mutations in Cas9 to alter its function is creating fusions of Cas9 with other proteins such as programmable DNA-binding domains (pDBD), which can be used to enhance the specificity of Cas9. For example, early studies showed that a Cas9 fusion with the FokI nuclease (fCas9) requires the simultaneous binding of two monomeric fCas9s 15--25 bp apart for cleavage, which greatly reduces off-target effects \[[@B191],[@B192]\]. This is similar to the 'paired nickase' approach, in which instead of having a single Cas9 nuclease, successful cleavage requires two mutated Cas9 proteins (which are nickases) localized by two independent sgRNAs \[[@B193]\]. A similar approach was utilized by Bolukbasi et al., where they examined the properties of fusions of SpCas9 with ZFPs and TALEs. Importantly, the authors simultaneously reduced the endogenous DNA-affinity of the Cas9, with the goal of broadening the sequence targeting range of the fusion protein, and show that this actually results in a significant increase in specificity \[[@B196]\]. Another interesting approach to increasing specificity of Cas9 is to create a fusion with chemically regulated proteins such as dihydrofolate reductase (DHFR) or the estrogen receptor (ER50), which are stabilized by trimethoprim (TMP) or 4-hydroxytamoxifen (4-HT), respectively. In the absence of these chemicals, the fusion proteins are targeted for degradation, thus reducing off-target effects by limiting the availability of the protein \[[@B197]\]. One disadvantage of fusion proteins is that they tend to be rather large, which can complicate delivery. Fusions of smaller Cas proteins (such as SaCas9 or Cas12a) with proteins that enhance targeting specificity could therefore be worth exploring. Fusion proteins are also further discussed in the context of base editors later in this review.

Until now, we have primarily focused on alterations to the protein component of CRISPR systems with the goal of increased specificity. However, parallel and equally justifiable efforts to increase the accuracy of CRISPR systems involve changing the structure of the sgRNA. The rules of sgRNA design are constantly evolving to improve specificity, with multiple groups contributing to this effort \[[@B195],[@B198]\]. In addition to sequence, the chemical composition of the sgRNA can also affect specificity. Multiple groups have shown that introducing RNA modifications such as 2′-O-methyl-ribonucleotides, 2′-fluoro-ribonucleotides, phosphorothioate ribonucleotides and others, can increase the stability of the sgRNA by conferring resistance to nucleases, but also improve specificity by affecting the interactions between the sgRNA, DNA, and Cas9 \[[@B201]\]. Yet another approach to sgRNA optimization involves introduction of secondary structure that can affect specificity. Recently, a study showed that engineering in a hairpin at the 5′ end of the sgRNA can alter secondary structure and thereby provide an energetic barrier to R-loop formation. This allows for greater specificity and fewer off-target effects \[[@B206]\]. The authors also show that this method can improve the specificity of *S. aureus* Cas9 and Cas12a, suggesting broader applicability for altering sgRNA design \[[@B206]\]. Each of the individual approaches to Cas optimization reviewed above have yielded significant improvements both in specificity and efficiency of CRISPR gene editing. It will be interesting to determine whether combinations of these solutions could synergize to produce even more hyperaccurate RNPs.

Looking to the future, there are hybrid CRISPR/transposase systems that can be co-opted in a similar fashion to those mentioned above for use in mammalian cells. Recent work has shown the natural occurrence of such systems in bacteria allowing for incorporation of longer fragments of DNA into the genome without the need for homology-directed repair (which requires double-stranded DNA breaks) \[[@B207],[@B208]\].

Base editors {#sec4-2}
------------

The CRISPR/Cas system has been successfully used to for homology-directed recombination (HDR)-based editing of the genome. This function is critical for correcting disease-causing mutations, but the low efficiency of HDR compared with non-homologous end-joining (NHEJ) in mammalian cells complicates using this method for repairing mutations \[[@B209]\]. Efforts to enhance usage of HDR, while significant and impactful, have only yielded moderate increases in efficiency \[[@B74],[@B210],[@B211]\]. An elegant solution to this problem was developed by David Liu of Harvard University, who demonstrating that fusing a cytidine deaminase (enzyme which deaminates a cytosine into a uracil) with catalytically inactive Cas9 (dCas9) could result in sgRNA-guided correction of a range of C to T mutations that are relevant to human disease \[[@B212]\]. This technology bypasses the need to make double-stranded breaks in the underlying DNA. Instead, the presence of a stretch of ssDNA in the R-loop of the dCas9 serves as a substrate for the cytidine deaminase (in this case, rat APOBEC1, which showed the highest activity of the four enzymes tried). Importantly, in contrast with the low efficiency of HDR, deamination-driven base editing showed 15--75% efficiency with minimal indels.

The Liu lab has since taken this technology a step further and developed a parallel adenine base editor system that can convert A•T into G•C in DNA. As there are no known adenine deaminases *in vivo*, this endeavor required directed evolution and engineering of a transfer RNA adenosine deaminase to be able to use DNA as a substrate \[[@B61]\]. The collection of modular base editing complexes developed by the Liu lab now enables all four transition mutations (purine to purine or pyrimidine to pyrimidine). Since these discoveries, a number of groups have developed and/or utilized similar dCas9/deaminase base editor systems, and shown efficient base editing in organisms ranging from bacteria to organoid systems to human embryos \[[@B22],[@B49],[@B62],[@B93],[@B213]\], which is extremely promising for therapeutic applications. More recently, BE-PACE (base editors through PACE) was used to identify and optimize base editors on both GC and non-GC target cytosines. They were able to successfully evolve three deaminases -- APOBEC1, FERNY, and CDA1, and showed that fusion of these evolved proteins with dCas9 enhanced base editing efficiency compared with their parental proteins \[[@B220]\]. The authors do caution, however, that editing efficiency is subject to cell type, cell state, and site specificity, meaning that each individual application may require pilot testing of a variety of base editors before the optimal one can be chosen. In addition, base editors have also been used for *ex vivo* applications such affinity maturation of antibodies \[[@B221]\].

As with all novel technology however, careful evaluation is required to avoid any unintended off-target effects. Two recent studies demonstrate that base editors, specifically cytosine base editors, cause an alarming number of unwanted, off-target mutations *in vivo*, both in plants and mice \[[@B222],[@B223]\]. Surprisingly, a new study found unwanted mutations in the RNA transcriptome as a result of off-target DNA base editing activity \[[@B224]\]. Of course, some of these effects could potentially be mitigated by reducing the dose of the base editing complex that is introduced, or by refining the components of the complex. Such efforts are already underway, with examples including the use of Sniper dCas9, a Cas9 with increased specificity created by directed evolution, or RNPs instead of plasmids to reduce to delivered dose \[[@B157],[@B225]\]. Furthermore, many of these off-target mutations may either be silent on non-consequential functionally, but these findings highlight the need for further research before base editors can be widely used in the clinic.

RNA targeting {#sec4-3}
-------------

While the development of CRISPR systems to target DNA across cell types and organisms for a variety of functions has undeniably revolutionized both basic scientific research and the development of therapeutics for clinical applications, the paramount importance of coding and non-coding RNAs in biology has made the discovery of RNA-targeting CRISPR systems an equally exciting area in the field of nucleic acid editing. Targeting of RNA by CRISPR systems is not only useful for altering levels of mRNAs and non-coding regulatory RNAs, but also represents a mechanism by which these edits can be temporally regulated, limited by the half-life of the targeted RNA (as opposed to genomic changes, which are permanent for the lifetime of the cell). While there are a number of known RNA-targeting CRISPR systems in bacteria, their adaptation for use in mammalian cell types is only now beginning to be explored \[[@B226]\]. There are both Class 1 (multi-component) and Class 2 (single component) RNA-targeting CRISPR systems \[[@B226]\]. Given the complexity of Class 1/Type III CRISPR systems and the resulting difficulty in expressing functional protein complexes heterologously, the majority of uses cases for these have been in prokaryotes \[[@B226]\]. On the other hand, Class 2 systems have been shown to target RNA, and are being successfully adapted for RNA-targeting in mammalian systems. Early work demonstrated that in the presence of a ssDNA oligonucleotide with a PAM sequence (PAMmer), SpCas9 could be 'tricked' into targeting ssRNAs for cleavage \[[@B227]\]. Using a similar PAMmer-based strategy, dSpCas9 can be targeted to various mRNAs for live tracking of transcripts within the cell \[[@B228]\]. More recently, it has been demonstrated that while the PAMmer enhances RNA-targeting of SpCas9, it is not required for this activity, as exemplified by the cleavage of repetitive RNAs and certain mRNAs \[[@B229],[@B230]\].

*S. pyogenes* is however, not the only organism with a Type II Cas9 that can be made to target RNA, and in fact, Cas9 from alternative sources have been shown to be amenable to RNA-targeting. Cas9 enzymes from *Staphylococcus aureus* (SaCas9), *Campylobacter jejuni* (CjCas9), *Francisella novicida* (FnCas9) and *Neisseria meningitidis* (NmCas9) have all been shown to have RNA-targeting activity to different extents \[[@B231]\]. NmCas9 has been demonstrated to target RNAs *in vitro* in the absence of any PAMmer or cofactors, although its endogenous activity *in vivo* remains to be determined \[[@B233]\]. CjCas9 on the other hand, has been shown to target endogenous mRNAs *in vivo* through imperfect pairing with native crRNA guides and subsequent cleavage by Cas9's HNH domain \[[@B231]\]. A step further is heterologous use of Cas9's RNA-targeting activity, as shown in one study where SaCas9 had a protective effect in *E. coli* from MS2 phage through cleavage of its RNA genome, as well as targeting of endogenous *E. coli* mRNAs \[[@B234]\]. When it comes to adaptation of these Type II Cas9s to a mammalian system, one of the few demonstrations is the use of FnCas9, which not only can target endogenous RNAs, but has been shown to target the genome of a human RNA virus, hepatitis C, in a liver carcinoma cell line \[[@B232]\]. If these Type II Cas9 enzymes are to be used clinically as RNA-targeting enzymes, future work should focus on efficiency and specificity (both in terms of sequence, and DNA vs RNA) in mammalian cells, with significant focus on off-target effects, as with all the other novel CRISPR systems that are discussed herein.

The issue of fine-tuning a CRISPR system to target RNA instead of DNA can be a challenge with dual-specificity Cas proteins. Another member group of the Class 2, single component CRISPR systems, the Type IV Cas13 proteins, helps bypass this difficulty by specifically targeting only RNA (not DNA). Two of the best characterized Cas13 proteins are *Leptotrichia wadei* Cas13a (LwaCas13a) and *Leptotrichia shahii* Cas13a (LshCas13a, previously known as LshC2c2), both studied by Abudayyeh et al [@B236]\]. Heterologous expression of LshCas13a was shown to degrade *E. coli* transcripts *in vivo*, as well as protect *E. coli* from MS2 phage infection \[[@B236]\]. LwaCas13a was expressed both in plant and mammalian cells, and successfully targeted endogenous and reporter genes in both these cell types \[[@B237]\]. Both these Cas13a proteins exhibit 'collateral RNA cleavage', meaning that their RNase activity causes degradation of any surrounding transcripts, and this collateral RNA cleavage is not specific for the target. This problem is circumvented by using Cas13b *Prevotella sp. P5-125* (PspCas13b), as shown by Cox et al., which exhibits specific RNase activity for its target without the collateral damage \[[@B238]\]. This study then uses a catalytically inactive version of PspCas13b fused with ADAR2 (adenosine deaminase acting on RNA type 2) for highly specific base editing of RNA from adenosine to inosine (A to I). The authors coin their system RNA Editing for Programmable A to I Replacement, or REPAIR, and further engineer the system for optimal viral delivery \[[@B238]\]. Future work will likely seek to expand the repertoire of based changes that can be achieved, for example, C-to-U editing by using a fusion of Cas13 with APOBEC \[[@B239]\].

Another group developed a systematic computational method to identify more RNA-targeting Type IV CRISPR systems, following which they engineered seven Cas13 orthologs, which resulted in a ribonuclease effector derived from *Ruminococcus flavefaciens* XPD3002 (CasRx) \[[@B240]\]. CasRx was used to knockdown a variety of endogenous transcripts and mammalian cells with enhanced efficiency and specificity compared with RNA interference (RNAi) and even CRISPR-mediated inhibition (CRISPRi) \[[@B240]\]. In an elegant demonstration of the therapeutic potential of their work, the authors show that CasRx can regulate the splicing of MAPT, the gene encoding the tau protein. The ratio of τ isoforms is critically mis-regulated in Frontotemporal Dementia, and CasRx can rescue this ratio in diseased cortical neurons, suggesting that this protein could potentially be used therapeutically in primary cells such as neurons, to reverse the effects of neurodegenerative disease \[[@B240]\]. This is also an excellent example of a situation in which DNA editing would be of no use, as splicing occurs at the level of RNA. Of course, before such a therapeutic can be deployed in patients, extensive work has to be done to eliminate off-target effects and ensure long-term safety, but taken together, these RNA-targeting CRISPR systems represent a new and exciting frontier in the clinical applications of gene editing.

CRISPR-mediated repression of gene expression {#sec4-4}
---------------------------------------------

Recent modifications to the CRISPR/Cas9 system have provided effective strategies for targeted control of gene expression, as opposed to editing of nucleic acid sequences. Central to CRISPR-mediated gene regulation is a mutated form of Cas9 that lacks endonuclease activity, called dead cas9 or dCas9. The dCas9 protein incorporates point mutations (D10A and H840A) in the RuvC and HNH nuclease domains, respectively \[[@B16]\]. Importantly, although dCas9 does not cleave DNA, it retains the ability to precisely bind specific DNA sequences through sgRNA targeting \[[@B241]\]. Targeted gene expression can be repressed by directing dCas9 to the promoter or protein coding region of a gene. When bound to a promoter, dCas9 blocks transcription initiation through the steric inhibition of transcription factors and RNA polymerase \[[@B241]\] ([Figure 6](#F6){ref-type="fig"}A). Alternatively, dCas9 bound to the protein coding region of a gene blocks transcription elongation when RNA polymerase collides with the dCas9-sgRNA complex \[[@B241]\]. Utilizing dCas9, or dCas9 fused to additional transcriptional repressors, to repress gene expression is the central tenet of CRISPRi.

![CRISPR/Cas9 regulators of gene expression\
(**A**) The nuclease dead version of Cas9, dCas9, is directed to a genomic locus with an sgRNA and inhibits transcription of a target gene. (**B**) Fusion of the KRAB domain to dCas9 causes stronger gene repression. CRISPR-mediated gene activation (CRISPRa) involves recruiting transcriptional activators to a genomic locus using a dCas9--sgRNA scaffold. (**C**) The simplest CRISPRa system is dCas9 fused to VP64. More complex CRISPRa systems include (**D**) Sun-Tag, (**E**) VPR and (**F**) SAM, and these involve the recruitment of multiple transcriptional activators to further enhance gene expression. Abbreviations: KRAB, Krüppel-associated box domain of Kox1; SAM, [S]{.ul}ynergistic [A]{.ul}ctivation [M]{.ul}ediator.](bsr-40-bsr20200127-g6){#F6}

Although dCas9 itself can be a powerful repressor of gene expression in bacteria, its ability to silence genes in mammalian cells is more modest \[[@B241],[@B242]\]. Control of eukaryotic gene expression includes additional layers of regulation involving recruitment of positive and negative transcriptional regulators, as well as epigenetic modifications to genomic DNA and histones. To more effectively knock down transcription in mammalian cells, the dCas9 molecule was further engineered to incorporate fusions with various effector protein domains as illustrated in [Figure 6](#F6){ref-type="fig"}A,B. Several fusions proteins were tested initially including dCas9 fused to the Krüppel-associated box domain of Kox1 (KRAB), the chromo shadow domain of HP1α (CS), the WRPW domain of Hes1, and four copies of the SIN3A domain of MAD1 (SID4X) \[[@B242],[@B243]\]. Of the dCas9-repressor constructs tested, the dCas9-KRAB fusion was shown to be most effective at repressing eukaryotic gene expression, and could knock down reporter and endogenous genes 5--15-fold in human cells \[[@B242]\] ([Figure 6](#F6){ref-type="fig"}B). The KRAB domain is broadly conserved across eukaryotic C2H2 ZFPs and exerts gene repression by interacting with chromatin-remodeling factors \[[@B244],[@B245]\]. The dCas9-KRAB system has become the gold-standard for mammalian gene knockdown studies, and has been used for diverse purposes including mapping human gene regulatory networks \[[@B246]\], tuning gene expression in human pluripotent stem cells \[[@B247]\], and silencing gene expression within a mouse brain \[[@B250]\].

New CRISPR interference technologies continue to emerge, and novel modifications to the dCas9 scaffold have been shown to enhance the efficacy of gene silencing. A recent study screened numerous effector domains fused to dCas9 and found that a synergistic fusion of dCas9-KRAB-MeCP2 could produce a 5--60 fold reduction in gene expression when compared with dCas9 alone \[[@B251]\]. These CRISPRi tools allow rapid knockdown of genes across diverse cell types and can silence regions of the genome that were historically difficult to target including non-coding RNAs, antisense transcripts and microRNAs.

CRISPR-mediated activation of gene expression {#sec4-5}
---------------------------------------------

The foundation of CRISPR-mediated gene activation (CRISPRa) is the dCas9 protein fused to one or more transcriptional activators. There are several CRISPRa systems currently in use ([Figure 6](#F6){ref-type="fig"}C--F), and each builds a unique synthetic transcription factor that can be targeted to the promoter of a gene of interest with an sgRNA. The first version of CRISPRa involved dCas9 fused to VP64, a strong transcriptional activator composed of tetrameric repeats of the activation domain of herpes simplex viral protein VP16 \[[@B193],[@B242],[@B252],[@B253]\] ([Figure 6](#F6){ref-type="fig"}C). The use of dCas9-VP64 has been shown to allow activation of target genes, although the level of gene expression is typically a modest two to five fold increase in mammalian cells \[[@B254]\]. Interestingly, multiplexing several sgRNAs that tile the promoter enhances gene activation, suggesting that recruitment of multiple dCas9-VP64 activators could increase gene expression \[[@B252],[@B255]\]. To recruit multiple copies of VP64 to a genomic locus, a novel CRISPRa system termed SunCas9, or SunTag, was developed \[[@B256],[@B257]\] ([Figure 6](#F6){ref-type="fig"}D). The SunTag module involves dCas9 fused to a protein scaffold composed of 10--24 repeating GCN4 peptide epitopes \[[@B256],[@B257]\]. The SunTag epitope array then recruits multiple copies of the nuclear localized GCN4 scFv antibody fused to a VP64 activator. Using the SunTag system a single dCas9 molecule is capable of recruiting numerous copies of VP64 to a target sequence, and considerably increases gene expression when compared with activation with the dCas9--VP64 fusion alone \[[@B257]\].

The next iterations of CRISPRa technologies involved combining multiple synergistic transcriptional activators with the sgRNA-directed dCas9. In one study, researchers surveyed the effects of numerous activation domains fused individually, and in combination, to dCas9 to increase gene activation \[[@B258]\]. A tripartite activator complex composed of [V]{.ul}P64, [p]{.ul}65, and [R]{.ul}ta fused in tandem, called VPR, was shown to increase gene expression of endogenous targets 22--320 fold when compared with dCas9--VP64 only \[[@B258]\] ([Figure 6](#F6){ref-type="fig"}E). Another CRISPRa approach called the [S]{.ul}ynergistic [A]{.ul}ctivation [M]{.ul}ediator (SAM) builds on the dCas9--VP64 fusion protein by adding multiple, distinct activation mechanisms \[[@B259]\] ([Figure 6](#F6){ref-type="fig"}F). Analysis of the crystal structure of the Cas9--sgRNA complex revealed that both the tetraloop and stem-loop 2 of the sgRNA have four base-pairs that inertly protrude outside of the Cas9 protein \[[@B183]\]. The exposed sgRNA loops were hypothesized to be capable of acting as scaffolds to recruit additional transcriptional activators. The SAM system utilizes the original dCas9--VP64 protein but incorporates an engineered sgRNA that contains minimal hairpin aptamers appended to the sgRNA tetraloop and stem-loop 2 \[[@B259]\]. The hairpin RNA aptamers can be selectively bound by an MS2 bacteriophage coat protein \[[@B260]\]. The MS2 protein is then fused to two additional transcriptional activators, p65 and the activation domain from the human heat-shock factor HSF1 \[[@B259]\]. Each sgRNA aptamer can bind two copies of the MS2 protein, thus allowing a total of four copies of MS2-p65-HSF1 fusion proteins to be recruited to each dCas9--VP64 activator complex \[[@B259]\]. Together, the SAM system utilizes a synergy of three distinct activation domains (VP64, p65, and HSF1) to generate a specific and powerful CRISPRa tool capable of activating genes more strongly than dCas9--VP64 by itself. CRISPRa technologies continue to be improved, but currently the SunTag, VPR, and SAM systems function relatively equally in terms of gene activation \[[@B261]\]. Importantly, across diverse eukaryotic species, the SunTag, VPR, and SAM systems are all capable of gene activation several orders of magnitude stronger than the first-generation dCas9-VP64 alone \[[@B261]\].

While most studies utilizing CRISPRa technologies in disease models have been focused on understanding how genes function at a cellular level, several studies have looked at the potential to use CRISPRa to modulate disease in mouse models. Use of CRISPRa systems resulted in increased gene expression that led to phenotypic changes in the mice, including mouse models of diabetes, muscular dystrophy, and acute kidney disease \[[@B262]\]. Recently, delivery of dCas9-VP64 targeted down-regulated genes in breast cancer resulted in increased gene expression and reduction in tumor growth in mouse xenografts \[[@B263]\]. Viral-based delivery of dCas9--VP64 has also been demonstrated to overcome haploinsufficiency in two obese mouse models. The resulting increase in expression from the existing normal copy of two different genes, Sim1 or Mc4r, prevented the development of obesity in the mouse models \[[@B264]\].

Epigenetic modifications using CRISPR tools {#sec4-6}
-------------------------------------------

The CRISPRi/a tools described above primarily function by directly recruiting or interfering with transcriptional machinery which is thought to result in short term alteration of gene expression limited to the duration of the CRISPRi or CRISPRa expression. However, most eukaryotes utilize additional epigenetic modifications to DNA and histones that are important regulators of gene expression. One of the most well-studied epigenetic modifications is the methylation of the fifth position of cytosine. In mammals, methylation can be deposited *de novo* by DNA methyltransferase (DNMT3A/B) and can be maintained by DNMT1 \[[@B265]\]. Demethylating DNA involves oxidation of the methyl group by TET dioxygenases, and restored by replication-dependent dilution or DNA glycosylase-initiated base excision repair \[[@B266]\]. Methylated DNA regulatory elements interfere with their trans-acting transcription factors causing gene repression \[[@B267]\]. The ability to edit the methylation at specific genomic loci would be a powerful capability to enable researchers to better control transcription in mammalian cells.

Targeted editing of DNA methylation has previously been accomplished with custom ZFPs or TALEs fused to DNA methyltransferases \[[@B268],[@B269]\]. However, designing new ZFPs or TALEs for every target sequence of interest would be expensive and laborious. Alternatively, several CRISPR/Cas9 tools have recently been engineered that allow editing of DNA methylation, and only require a custom sgRNA for targeting to genomic loci of interest. The first generation of CRISPR-based methylation systems in mammalian cells used dCas9 fused to full-length DNMT3a or the DNMT3a catalytic domain \[[@B270]\]. Importantly, these dCas9-based methylation tools have been shown to function with higher efficacy and resolution, and also more effectively silence gene expression than the TALE-based approaches \[[@B271]\]. The dCas9-DNMT3A fusions can accurately methylate DNA across a region of ∼35--320 bp from the DNA-bound fusion protein and can be multiplexed with several sgRNAs to span a larger target region of the genome \[[@B270]\]. Alternatively, methylation across a larger genomic region can be edited using the dCas9-SunTag-DNMT3A system, that can recruit multiple DNMT3As to a target site and hypermethylated a region of ∼4.5 kb \[[@B274],[@B275]\]. Multimerization can also improve methylation and using dCas9-DNMT3a/DNMT3L could lead to more potent and widespread DNA methylation of CpG islands, and additionally caused DNA methylation spreading from a target site \[[@B276]\]. Importantly, it is heritable across mitotic divisions \[[@B270]\].

A limitation to the first-generation dCas9-DNMT fusion proteins is that they function relatively slowly over a period of several days, which may impede experimental systems that require analyses over shorter time durations. Additionally, recent analyses of genome-wide methylation patterns arising from dCas9-DNMT systems identified numerous off-target effects that are common in promoters, CpG islands and 5′ untranslated regions \[[@B277],[@B278]\]. Off target effects of dCas9-DNMT3A may arise because dCas9 is not required to be bound to its sgRNA-target sequence in order to function, so dCas9-DNMT3A bound to other genomic loci are free to promote methylation \[[@B279]\]. Additional off target effects may arise because DNMT3A functions as a tetramer and can recruit endogenous DNMT3A/DNMT3L proteins to methylate larger regions \[[@B270]\]. Several recent iterations of dCas9 DNA methyltransferases have attempted to increase enzyme kinetics and resolve off target effects. To increase the rate of DNA methylation, new CRISPR tools incorporated an engineered *de novo* CpG DNA methyltransferase from the bacterial species *Mollicutes spiroplasma* strain MQ1 (M.sssI) \[[@B280]\]. The modified MQ1^Q147L^ DNA methyltransferase is relatively small in size (386 amino acids), functions rapidly within 24 hours, and produces fewer off-target effects \[[@B280]\]. The dCas9-MQ1^Q147L^ fusion protein was demonstrated to efficiently methylate target DNA sequences in human cells and developing mouse embryos \[[@B280]\]. Bacterial derived MTases are not expected to recruit endogenous mammalian MTases which may help to limit off-target demethylation. To further reduce off-target events, a split version of the M.sssI MTase was shown to generate efficient and targeted DNA methylation (up to ∼70%) \[[@B279]\]. The split MTase system involves one fragment of M.sssI fused to dCas9 which then directs the assembly of the MTase fragments when bound to target DNA loci \[[@B279]\]. Additionally, this system further reduces off target events because the two M.SssI fragments lack stability or ability to methylate DNA when dCas9 is not bound to DNA \[[@B279]\].

Targeted demethylation in mammalian genomes has also been accomplished with several technical variations, but all methods described here involve recruiting the TET1 dioxygenase to specific genomic loci guided by sgRNA and dCas9. Similar to the methylation strategies described above, targeted demethylation was previously demonstrated using TALE-TET1 fusion proteins in human cells \[[@B281]\]. CRISPR-based demethylation editors subsequently emerged that involved protein fusions with dCas9 and the catalytic domain of TET1 (TET1CD), and these dCas9-TET1 systems both demethylated target DNA and activated gene expression in cancer cell lines, mouse embryonic stem cells, mouse cortical neurons, and *in vivo* in mice \[[@B272],[@B282]\]. The dCas9-TET1 fusion protein was directly compared with a TALE-TET1 fusion, and the CRISPR-based approach was determined to demethylate DNA more effectively and accurately than the TALE-based approach (28% decreased methylation within 150 bp vs. 14% within 200 bp, respectively) \[[@B272]\]. A second CRISPR-based demethylation method involved repurposing the SunTag system to recruit multiple TET1CD molecules to a genomic locus \[[@B283]\]. The SunTag-TET1 system was capable of more long-range demethylation when compared to TALE-based methods, likely because up to ten copies of TET1 could be recruited to a target sequence \[[@B283]\]. The SunTag-TET1 system was also shown to more effectively demethylate DNA than the direct dCas9-TET1CD fusion protein (\>90% max observed demethylation vs. 14%, respectively) \[[@B283]\]. Importantly, in addition to demethylating DNA, the SunTag-TET1CD was also demonstrated to modify gene expression, and could induce a 1.7--50 fold up-regulation of target genes in diverse mammalian cell types and *in vivo* in brain of mouse fetuses \[[@B283]\]. Finally, a third demethylation approach repurposed the SAM system to recruit MS2-TET1CD to the MS2 aptamers protruding from the dCas9--sgRNA complex \[[@B284]\]. The MS2-TET1CD demethylation system was also shown to promote demethylation and activate gene expression, although it was not as effective as the SunTag system \[[@B283],[@B284]\]. Together there are many variations of CRISPR-based DNA methylation editors, however in order to construct a desired epigenetic landscape, the cooperation between methylation and demethylation editors is likely necessary. For example, a recent study using mouse embryonic stem cells demonstrated that a synergy between TET1 and DNMTs was necessary to properly define and edit regions of genome methylation \[[@B285]\].

Altering the state of chromatin through modifications to histone proteins is another epigenetic mechanism to control proper gene expression in eukaryotes. Numerous histone modifications are involved with directing mammalian gene expression, but the majority of current CRISPR-based histone editing involves acetylation or methylation of lysine residues. When terminal lysine residues of histone proteins are acetylated, their charge becomes more neutral which weakens the interaction between histones and DNA and can subsequently become more permissive for transcription \[[@B286]\]. Permissive and repressive chromatin states are mediated in part by histone acetyltransferases and histone deacetylases, and these enzymes have been repurposed into novel CRISPR tools. The first CRISPR-based histone modifier was dCas9 fused to the catalytic core of the human histone acetyltransferase p300 (dCas9^p300\ Core^) ^\[^[@B287]^\]^. Notably, use of dCas9^p300\ Core^ could significantly increase target gene expression in human cells due to acetylation of H3K27 residues from gene promoters as well as both proximal and distal enhancers \[[@B287]\]. Additionally, the dCas9 transcriptional activators described above typically require the recruitment of multiple effector domains or multiple sgRNAs to promote robust gene expression, while the dCas9^p300\ Core^ system needs only a single gRNA to function effectively \[[@B287]\]. CRISPR-mediated histone deacetylation tools have also been developed using dCas9 fused to the full-length human histone deacetylase HDAC3 \[[@B288]\]. Importantly, the dCas9-HDAC3 fusion protein was demonstrated to remove H3K27ac marks when positioned properly in a gene promoter, and could modify gene expression in mouse and human cell lines \[[@B288]\]. Unlike the dCas9-based transcriptional activators/repressors, the positioning of the sgRNA relative to the transcription start site of a gene does not appear to influence function, however the positioning relative to endogenous histone acetylation was crucial \[[@B288]\].

Another modification to histone proteins that regulates chromatin accessibility and local gene expression is the methylation of lysine residues. Histone modifying enzymes including methyltransferases and demethylases are conserved proteins that control histone methylation and can be engineered to be used as programmed histone-modifying enzymes. Recent developments to the CRISPR-based epigenetic toolbox includes both histone demethylases and methyltransferases fused to dCas9. The human protein lysine-specific histone demethylase (LSD1) is a broadly conserved lysine-specific histone demethylase and transcriptional co-repressor, and silences enhancer elements through H3K4/K9 specific demethylation \[[@B289]\]. An engineered TALE-LSD1 was shown to edit active enhancers and modify gene expression \[[@B292]\]. Soon afterward, a dCas9-LSD1 fusion protein was developed that could allow for more high-throughput histone demethylation editing \[[@B293]\]. The dCas9-LSD1 protein was demonstrated to effectively remove histone methylation from enhancer regions and knock down gene expression in mouse embryonic stem cells \[[@B293]\]. Alternatively, methylation of specific lysine residues on histone 3 proteins (e.g., H3K4me3 and H3K79me2-3) are associated with transcriptionally active euchromatin \[[@B291]\]. PRDM9 is a histone lysine methyltransferase that possesses mono-, di-, and trimethylation activities at H3K4 residues \[[@B294]\]. The functional domain of the human PRDM9 was recently fused to dCas9, and could produce targeted H3K4me3 marks at promoter regions that activated expression from previously silenced genes in human cell lines \[[@B295]\]. Methylation of other specific histone residues can alternatively create repressive chromatin (e.g., H3K9me3 and H3K27m3) leading to gene silencing \[[@B291]\]. Recently, O'Geen et al. engineered a broad set of epigenetic writers and recruiters fused to dCas9, and investigated their ability to edit H3K9me3 and H3K27me3 marks and to modify gene expression \[[@B296]\]. Interestingly, this work demonstrated that all of the methyltransferases tested (EZH2, G9A, SUV39H1, and FOG1) were all capable of some level of transcriptional repression, although they did not always correlate with expected histone modifications \[[@B296]\]. Additionally, some of the epigenetic editors tested only provided temporary silencing, but combinations of effectors could overcome this transient effect and promoted long-lasting repression \[[@B296]\]. Engineering a desired and persistent cell state is a complex and challenging effort and will likely require the use of multiplexed epigenetic modifiers targeted to both enhancer and promoter regions.

Similar to the status with CRISPRi and CRISPRa technologies, the application of Cas9 epigenome editors has mostly been pursued *in vitro* to date. However, the potential to selectively silence a mutated gene or activate the healthy gene copy with long duration effects has vast potential in medicine that could be achieved as CRISPR epigenome editing technology advances.

Conclusions {#sec5}
===========

The rapid development of gene editing technologies within the last decade is already providing significant advances toward improving human health. Gene editors are being used in ongoing clinical trials to treat diverse human diseases including HIV, cancer, and blood disorders. As gene editing tools continue to evolve, novel therapies for additional diseases will likely emerge. CRISPR-based gene editing tools, in particular, are quickly developing and have been used to generate diverse modifications in mammalian cells, including targeted editing of specific DNA sequences, activation or repression of genes of interest, and epigenetic reprogramming of cellular identities. However, despite the potential benefits of using gene editing technologies for human therapy, the fundamental biology underlying these technologies needs to be better understood in order to provide safe and effective treatment options to patients. Many of the CRISPR tools have been tested only *in vitro* and an outstanding question is the efficacy and safety during *in vivo* applications. This will likely involve the complex interplay between a given tool's molecular function combined with the delivery modality. Some CRISPR components have been immunogenic in certain individuals -- how can we engineer these potential therapies to minimize the risk of eliciting a counterproductive immune response? CRISPR gene-editing tools often exhibit widespread off-target effects, which could be dangerous if these therapies are needed in vital organs or are delivered there unintentionally -- how can we maximize delivery to targeted body sites and minimize accumulation at off-target sites? These issues are all currently being investigated by research groups across the globe, and improvements in these areas will be crucial for the success of gene-editing therapies.

Ethical issues also arise from this recent wave of new gene-editing tools. Is it ethical to edit a developing human embryo? Who should make these decisions, and who will regulate them? There will need to be global discussions bridging science and politics to govern the use of CRISPR and gene editing in developing babies. Furthermore, health and disease are often a spectrum rather than a binary condition, and decisions must be made on the basis of known or likely trade-offs. Gene editing carries significant risks, such that a balance between acceptable risk for significant benefit must be struck in each case of potential use. This balance will shift as the technology advances, changing the risk/benefit profile for a given therapy.

Finally, as new technologies emerge there is always the possibility that they will be accidentally or intentionally misused. Ongoing work to identify and engineer anti-CRISPRs, such as that comprising DARPA's Safe Genes program, is already revealing the path forward to development of countermeasures that inhibit or reverse unwanted gene editing. Gene editing technologies are extremely powerful and hold immense potential to provide new opportunities to treat a myriad of human diseases. As the amount of resources devoted toward better understanding and characterization of these technologies continues to increase dramatically with every passing year, their full-fledged clinical deployment appears very close to becoming a reality.
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AATD

:   α-1 antitrypsin deficiency

AAV

:   adeno-associated virus

AAVS1

:   adeno-associated virus integration site 1

ACT

:   adoptive T-cell transfer

B2M

:   β-2 microglobulin

CAR

:   chimeric antigen receptor

CasRx

:   *Ruminococcus flavefaciens* XPD3002

CF

:   cystic fibrosis

CGD

:   chronic granulomatous disease

CjCas9

:   *Campylobacter jejuni* Cas9

CORD6

:   cone--rod dystrophy

CRISPR

:   clustered regularly interspaced short palindromic repeat DNA sequences

CRISPRa

:   CRISPR-mediated gene activation

CRISPRi

:   CRISPR-mediated gene inhibition

dCas9

:   catalytically inactive Cas9

dCas9^p300\ Core^

:   dCas9 fused to the catalytic core of the human histone acetyltransferase p300

DISCOVER-seq

:   Discovery of In Situ Cas Off-targets and VERification by sequencing

DMD

:   Duchenne muscular dystrophy

DNMT3A/B

:   DNA methyltransferase

fCas9

:   Cas9 fusion with the FokI nuclease

FDA

:   U.S. Food and Drug Administration

FnCas9

:   *Francisella novicida* Cas9

GvHD

:   graft-versus-host disease

HBB

:   β-globin gene

HDR

:   homology-directed recombination

HLA

:   human leukocyte antigen

HPFH

:   hereditary persistence of fetal hemoglobin

KRAB

:   Krüppel-associated box domain of Kox1

LCA10

:   Leber congenital amaurosis type 10

LNP

:   lipid nanoparticle

LSD1

:   lysine-specific histone demethylase

LshCas13a, previously known as LshC2c2

:   *Leptotrichia shahii* Cas13a

LwaCas13a

:   *Leptotrichia wadei* Cas13a

M.sssI

:   *Mollicutes spiroplasma* strain MQ1

NmCas9

:   *Neisseria meningitidis* Cas9

PACE

:   phage-assisted continuous evolution

PAMmer

:   ssDNA oligonucleotide with a PAM sequence

PD-1

:   programmed cell death protein 1

PD-L1

:   PD-1 ligand

PID

:   primary immunodeficiency

PspCas13b

:   *Prevotella sp.* Cas13b

RNP

:   ribonucleoprotein

SaCas9

:   *Staphylococcus aureus* Cas9

SAM

:   [S]{.ul}ynergistic [A]{.ul}ctivation [M]{.ul}ediator

scFv

:   single-chain variable fragment

SCID-X1

:   X-linked severe combined immunodeficiency

SpCas9

:   *Streptococcus pyogenes* Cas9

TALE

:   transcription activator-like effector protein

TALEN

:   transcription activator-like effector nuclease

TCR

:   T-cell receptor

TET1CD

:   catalytic domain of TET1

TIL

:   tumor-infiltrating lymphocyte

TRAC

:   TCR α constant

TRBC

:   TCR β constant

UDiTaS

:   uni-directional targeted sequencing

WAS

:   Wiskott--Aldrich syndrome

ZFN

:   zinc-finger nuclease

ZFP

:   zinc finger protein
